US7404950B2
(en)
|
2003-02-18 |
2008-07-29 |
Baylor College Of Medicine |
Induced activation in dendritic cell
|
US20130266551A1
(en)
*
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
CA2700573C
(en)
|
2006-09-26 |
2016-11-22 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
CA2700579A1
(en)
|
2006-09-28 |
2008-04-03 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
DK2279253T3
(en)
|
2008-04-09 |
2017-02-13 |
Maxcyte Inc |
Construction and application of therapeutic compositions of freshly isolated cells
|
DK2328923T3
(en)
|
2008-09-02 |
2016-03-21 |
Cedars Sinai Medical Center |
CD133 epitopes
|
US8415150B2
(en)
*
|
2009-02-24 |
2013-04-09 |
The Trustees Of The University Of Pennsylvania |
Methods for treating progressive multifocal leukoencephalopathy (PML)
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
WO2012054509A2
(en)
|
2010-10-22 |
2012-04-26 |
Dana-Farber Cancer Institute, Inc. |
Discovery of regulatory t cells programmed to suppress an immune response
|
DK3214091T3
(en)
*
|
2010-12-09 |
2019-01-07 |
Univ Pennsylvania |
USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
|
EP3907297A1
(en)
|
2011-04-15 |
2021-11-10 |
The Johns Hopkins University |
Safe sequencing system
|
EP2768863B1
(en)
|
2011-10-20 |
2017-09-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Anti-cd22 chimeric antigen receptors
|
WO2013063419A2
(en)
*
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
EA201491572A1
(ru)
|
2012-02-22 |
2014-12-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции и способы получения устойчивой популяции t-клеток, используемых для лечения злокачественного новообразования
|
CA2864489C
(en)
*
|
2012-02-22 |
2023-08-08 |
The Trustees Of The University Of Pennsylvania |
Use of the cd2 signaling domain in second-generation chimeric antigen receptors
|
EP2817338B1
(en)
|
2012-02-24 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Dll3 modulators and methods of use
|
CA2868121C
(en)
*
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
CA2869562C
(en)
*
|
2012-04-11 |
2023-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
MX370265B
(es)
|
2012-05-25 |
2019-12-09 |
Cellectis |
Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia.
|
CA2876734A1
(en)
*
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Use of cart19 to deplete normal b cells to induce tolerance
|
EP2872617A4
(en)
*
|
2012-07-13 |
2015-12-09 |
Univ Pennsylvania |
EXTENSION OF EPITOPES IN RELATION TO T CAR LYMPHOCYTES
|
BR112015000638A2
(pt)
|
2012-07-13 |
2017-08-08 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, célula, métodos para estimular uma resposta imune mediada pela célula t e uma população de célula alvo ou tecido em um mamífero, para provimento de imunidade antitumor em um mamífero, para tratamento de um mamífero que tenha uma doença, distúrbio ou condição associado com uma expressão elevada de um antígeno de tumor
|
BR112015000660A8
(pt)
|
2012-07-13 |
2022-03-15 |
Childrens Hospital Philadelphia |
uso de uma terapia de primeira linha e uma terapia de segunda linha para tratamento de um paciente possuindo uma doença, desordem ou condição associada com uma expressão elevada de um antígeno de tumor, e de uma composição para reduzir ou evitar um efeito adverso associado com a administração de uma célula geneticamente modificada para expressar um car.
|
BR112015000505A2
(pt)
*
|
2012-07-13 |
2017-06-27 |
Univ Pennsylvania |
método de analisar uma célula t geneticamente modificada para detectar um contaminante
|
IN2014DN10889A
(pl)
*
|
2012-07-13 |
2015-09-11 |
Univ Pennsylvania |
|
HUE053439T2
(hu)
|
2012-08-20 |
2021-06-28 |
Hutchinson Fred Cancer Res |
Sejtes immunterápiára szolgáló eljárás és készítmények
|
BR112015004522A2
(pt)
*
|
2012-09-04 |
2017-11-21 |
Cellectis |
receptor de antígeno quimérico multicadeia e usos destes
|
CN104955845B
(zh)
*
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
WO2014052545A2
(en)
|
2012-09-28 |
2014-04-03 |
Dana-Farber Cancer Institute, Inc. |
Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
|
WO2014055442A2
(en)
*
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
WO2014055771A1
(en)
*
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
CA2889055C
(en)
*
|
2012-10-24 |
2024-01-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
M971 chimeric antigen receptors
|
CN104956225B
(zh)
|
2012-10-29 |
2018-10-02 |
约翰·霍普金斯大学 |
卵巢和子宫内膜癌的帕帕尼科拉乌测试
|
AU2015210373B2
(en)
*
|
2012-12-20 |
2017-04-06 |
Celgene Corporation |
Chimeric antigen receptors
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
EP3985028A1
(en)
*
|
2013-02-06 |
2022-04-20 |
Celgene Corporation |
Modified t lymphocytes having improved specificity
|
US10137182B2
(en)
|
2013-02-14 |
2018-11-27 |
Immunocellular Therapeutics, Ltd. |
Cancer vaccines and vaccination methods
|
CA2901115A1
(en)
|
2013-02-15 |
2014-08-21 |
The Regents Of The University Of California |
Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof
|
US9394368B2
(en)
|
2013-02-20 |
2016-07-19 |
Novartis Ag |
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
|
EP2958942B1
(en)
|
2013-02-20 |
2020-06-03 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
AU2014218730B2
(en)
|
2013-02-22 |
2018-12-13 |
Abbvie Stemcentrx Llc |
Novel antibody conjugates and uses thereof
|
RU2680010C2
(ru)
|
2013-02-26 |
2019-02-14 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы иммунотерапии
|
EP3447072A3
(en)
*
|
2013-03-05 |
2019-05-22 |
Baylor College of Medicine |
Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
CA2905352A1
(en)
|
2013-03-14 |
2014-09-25 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling t cell proliferation
|
US9499855B2
(en)
*
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
WO2014153114A1
(en)
*
|
2013-03-14 |
2014-09-25 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
EP2970372B1
(en)
*
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modified t lymphocytes
|
US20150064153A1
(en)
|
2013-03-15 |
2015-03-05 |
The Trustees Of Princeton University |
High efficiency microfluidic purification of stem cells to improve transplants
|
NZ712693A
(en)
|
2013-03-15 |
2021-07-30 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for immunotherapy
|
CN105264127B
(zh)
|
2013-03-15 |
2019-04-09 |
Gpb科学有限责任公司 |
颗粒的片上微流体处理
|
CN113512522A
(zh)
|
2013-03-15 |
2021-10-19 |
普林斯顿大学理事会 |
用于高通量纯化的方法和设备
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US9657105B2
(en)
*
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
TWI654206B
(zh)
*
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
PL2992020T3
(pl)
*
|
2013-05-03 |
2020-06-01 |
Ohio State Innovation Foundation |
Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1
|
AU2014262469B2
(en)
|
2013-05-10 |
2019-11-14 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
EP2997141B1
(en)
*
|
2013-05-13 |
2022-10-12 |
Cellectis |
Cd19 specific chimeric antigen receptor and uses thereof
|
US11311575B2
(en)
*
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
KR102095700B1
(ko)
|
2013-05-14 |
2020-04-01 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
가공된 키메라 항원 수용체 (car) t-세포의 인간 적용
|
SG11201509609SA
(en)
*
|
2013-05-24 |
2015-12-30 |
Univ Texas |
Chimeric antigen receptor-targeting monoclonal antibodies
|
KR102301464B1
(ko)
|
2013-06-10 |
2021-09-14 |
다나-파버 캔서 인스티튜트 인크. |
종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
CA2922547C
(en)
|
2013-08-28 |
2020-03-10 |
Stemcentrx, Inc. |
Site-specific antibody conjugation methods and compositions
|
CA3173052A1
(en)
|
2013-08-30 |
2015-03-05 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
EP3620470B1
(en)
|
2013-10-11 |
2023-07-26 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Tem8 antibodies and their use
|
CA2927543C
(en)
|
2013-10-15 |
2021-07-20 |
The California Institute For Biomedical Research |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
US20150238631A1
(en)
*
|
2013-10-15 |
2015-08-27 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
SG11201602979RA
(en)
*
|
2013-10-17 |
2016-05-30 |
Univ Singapore |
Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
|
US10144770B2
(en)
*
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
CN104561069A
(zh)
*
|
2013-10-23 |
2015-04-29 |
深圳先进技术研究院 |
含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
BR112016010716A8
(pt)
|
2013-11-13 |
2020-04-22 |
Novartis Ag |
dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
AU2014352638B2
(en)
|
2013-11-25 |
2018-08-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control HIV infection
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
JP6943568B2
(ja)
|
2013-12-06 |
2021-10-06 |
アメリカ合衆国 |
胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法
|
TWI672379B
(zh)
*
|
2013-12-19 |
2019-09-21 |
瑞士商諾華公司 |
人類間皮素嵌合性抗原受體及其用途
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
KR20160101073A
(ko)
|
2013-12-20 |
2016-08-24 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
WO2015092024A2
(en)
*
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
CA2936501A1
(en)
*
|
2014-01-13 |
2015-07-16 |
Stephen J. Forman |
Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
US10323077B2
(en)
|
2014-02-10 |
2019-06-18 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
PT3105317T
(pt)
*
|
2014-02-14 |
2019-02-27 |
Cellectis |
Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas
|
AU2015218365A1
(en)
|
2014-02-14 |
2016-09-01 |
Immune Design Corp. |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
CN106132423B
(zh)
*
|
2014-02-14 |
2020-07-31 |
贝里坤制药股份有限公司 |
用诱导型嵌合多肽活化t细胞的方法
|
WO2015123642A1
(en)
*
|
2014-02-14 |
2015-08-20 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
US10196608B2
(en)
|
2014-02-21 |
2019-02-05 |
Cellectis |
Method for in situ inhibition of regulatory T cells
|
EP3107576A4
(en)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
CN103820393B
(zh)
*
|
2014-02-24 |
2016-09-07 |
西比曼生物科技(上海)有限公司 |
工程化cd20靶向性的nkt细胞及其制备方法和应用
|
US10532088B2
(en)
|
2014-02-27 |
2020-01-14 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
|
CN104877028A
(zh)
*
|
2014-02-28 |
2015-09-02 |
百奥迈科生物技术有限公司 |
抗dota嵌合抗原受体修饰的t细胞及其抗肿瘤的应用
|
US20230026111A1
(en)
|
2014-03-05 |
2023-01-26 |
Autolus Limited |
Methods
|
CN112094347A
(zh)
*
|
2014-03-05 |
2020-12-18 |
奥托路斯有限公司 |
具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
WO2015143224A1
(en)
*
|
2014-03-19 |
2015-09-24 |
Ambrx, Inc. |
Chimeric antigen receptor-modified t-cells
|
EP3569619B1
(en)
|
2014-03-19 |
2021-05-26 |
Cellectis |
Method of producing cd123 specific car t cells for cancer immunotherapy
|
BR112016021717A2
(pt)
|
2014-03-21 |
2018-07-10 |
Abbvie Inc |
anticorpos anti-egfr e conjugados anticorpo-fármaco
|
BR112016022369A2
(pt)
*
|
2014-04-03 |
2017-10-10 |
Cellectis |
receptores quiméricos de antígeno cd33-específicos para imunoterapia contra o câncer
|
ES2876263T3
(es)
|
2014-04-07 |
2021-11-12 |
Novartis Ag |
Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
|
KR102294483B1
(ko)
*
|
2014-04-07 |
2021-08-27 |
미네르바 바이오테크놀로지 코포레이션 |
항-nme 항체
|
JP2017515464A
(ja)
*
|
2014-04-10 |
2017-06-15 |
シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート |
細胞免疫療法のための方法および組成物
|
CA2945620C
(en)
*
|
2014-04-14 |
2022-12-06 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
SG11201608862SA
(en)
|
2014-04-23 |
2016-11-29 |
Juno Therapeutics Inc |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
US20170049819A1
(en)
*
|
2014-04-25 |
2017-02-23 |
Bluebird Bio, Inc. |
Kappa/lambda chimeric antigen receptors
|
DK3689899T3
(da)
|
2014-04-25 |
2021-11-22 |
2Seventy Bio Inc |
Kimære mnd-promotor-antigenreceptorer
|
JP6817069B2
(ja)
|
2014-04-25 |
2021-01-20 |
ブルーバード バイオ, インコーポレイテッド |
養子細胞療法薬を製造するための改善された方法
|
WO2015167766A1
(en)
*
|
2014-04-29 |
2015-11-05 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies
|
CN107074929B
(zh)
*
|
2014-05-02 |
2021-09-03 |
宾夕法尼亚大学董事会 |
嵌合自身抗体受体t细胞的组合物和方法
|
CN106459173A
(zh)
|
2014-05-02 |
2017-02-22 |
爱默蕾大学 |
人源化可变淋巴细胞受体(vlr)及其相关组合物和用途
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
CA2947290A1
(en)
|
2014-05-05 |
2015-11-12 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
EP3209641A4
(en)
|
2014-05-05 |
2018-06-06 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
|
DE112014006656B4
(de)
*
|
2014-05-14 |
2018-05-17 |
Carsgen Therapeutics Limited |
Nukleinsäure zur Kodierung eines chimären Antigen-Rezeptor-Proteins und T-Lymphozyt zur Expression eines chimären Antigen-Rezeptor-Proteins
|
CA2948462A1
(en)
|
2014-05-15 |
2015-11-19 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
EP3798233A1
(en)
|
2014-06-02 |
2021-03-31 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptors targeting cd-19
|
CN111394317A
(zh)
|
2014-06-06 |
2020-07-10 |
蓝鸟生物公司 |
改善的t细胞组合物
|
WO2015193406A1
(en)
*
|
2014-06-17 |
2015-12-23 |
Cellectis |
Cd123 specific multi-chain chimeric antigen receptor
|
GB201506423D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
SG11201700416TA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
AU2015292811B2
(en)
*
|
2014-07-21 |
2019-12-19 |
Novartis Ag |
Treatment of cancer using a CLL-1 chimeric antigen receptor
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
CN106687483B
(zh)
|
2014-07-21 |
2020-12-04 |
诺华股份有限公司 |
使用人源化抗-bcma嵌合抗原受体治疗癌症
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
DK3453406T3
(da)
*
|
2014-07-29 |
2021-07-12 |
Cellectis |
ROR1(NTRKR1)-specifikke kimære antigenreceptorer til cancerimmunterapi
|
CN107074973A
(zh)
*
|
2014-07-29 |
2017-08-18 |
辉瑞大药厂 |
用于癌症免疫疗法的EGFRvIII特异性嵌合抗原受体
|
CA2956482A1
(en)
|
2014-07-31 |
2016-02-04 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
AU2015308899B2
(en)
|
2014-08-27 |
2020-05-28 |
Dana-Farber Cancer Institute, Inc. |
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
EP2990416B1
(en)
*
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
IL250833B
(en)
|
2014-08-29 |
2022-09-01 |
Univ Texas |
Administering enzymes to reduce the level of kynurenine in the treatment of tumors
|
US10888608B2
(en)
*
|
2014-09-02 |
2021-01-12 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
|
JP6810685B2
(ja)
*
|
2014-09-04 |
2021-01-06 |
セレクティスCellectis |
癌免疫療法のための栄養膜糖タンパク質(5t4、tpbg)特異的キメラ抗原受容体
|
MA40595A
(fr)
|
2014-09-09 |
2021-05-26 |
Unum Therapeutics |
Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
|
WO2016040880A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
WO2016044383A1
(en)
|
2014-09-17 |
2016-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 antibodies (b7h3)
|
DK3194443T3
(da)
*
|
2014-09-17 |
2021-09-27 |
Novartis Ag |
Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi
|
KR20170057351A
(ko)
|
2014-09-19 |
2017-05-24 |
시티 오브 호프 |
IL13Rα2를 표적화하는 공자극 키메라 항원 수용체 T 세포
|
PL3200815T3
(pl)
|
2014-10-02 |
2021-10-18 |
The Wistar Institute Of Anatomy And Biology |
Sposoby i kompozycje do leczenia nowotworu
|
BR112017006664A2
(pt)
|
2014-10-03 |
2017-12-26 |
Novartis Ag |
terapias de combinação
|
JP2017531430A
(ja)
*
|
2014-10-07 |
2017-10-26 |
セレクティスCellectis |
Carによって誘導される免疫細胞の活性を調節するための方法
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
ES2751945T3
(es)
|
2014-10-09 |
2020-04-02 |
Univ Yamaguchi |
Vector de expresión de un RAQ y células T que expresan un RAQ
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
CN117427091A
(zh)
|
2014-10-20 |
2024-01-23 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗中的给药的组合物和方法
|
ES2910227T3
(es)
|
2014-10-31 |
2022-05-12 |
Univ Pennsylvania |
Composición y métodos para la estimulación y expansión de células T
|
CN114836385A
(zh)
|
2014-10-31 |
2022-08-02 |
宾夕法尼亚大学董事会 |
改变cart细胞中的基因表达及其用途
|
US20170363629A1
(en)
*
|
2014-11-05 |
2017-12-21 |
Board Of Regents, The University Of Texas System |
Biomarkers and targets for cancer immunotherapy
|
US10570186B2
(en)
|
2014-11-05 |
2020-02-25 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (CAR) to selectively target protein complexes
|
US20170333480A1
(en)
|
2014-11-05 |
2017-11-23 |
Board Of Regents, The University Of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
PL3215601T3
(pl)
|
2014-11-05 |
2020-11-02 |
Juno Therapeutics, Inc. |
Sposoby transdukcji i przetwarzania komórek
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
EP3218005B1
(en)
|
2014-11-12 |
2023-01-04 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
CN105601746B
(zh)
*
|
2014-11-21 |
2021-02-19 |
三生国健药业(上海)股份有限公司 |
一种嵌合Fc受体的融合蛋白及其制备方法和应用
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
CN107206025A
(zh)
|
2014-12-03 |
2017-09-26 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的方法和组合物
|
SG10202007326QA
(en)
|
2014-12-05 |
2020-08-28 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
|
EP3227324A4
(en)
|
2014-12-05 |
2018-08-29 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting g-protein coupled receptor and methods of use
|
SI3226897T1
(sl)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
EP3227432B1
(en)
|
2014-12-05 |
2023-10-11 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
AU2015357485B2
(en)
|
2014-12-05 |
2020-10-15 |
City Of Hope |
CS1 targeted chimeric antigen receptor-modified T cells
|
SI3230310T1
(sl)
*
|
2014-12-08 |
2019-11-29 |
Us Health |
Anti-CD70 himerni antigenski receptorji
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
EA036379B1
(ru)
|
2014-12-12 |
2020-11-02 |
Блубёрд Био, Инк. |
Химерные антигенные рецепторы к bcma
|
EP3234120A4
(en)
|
2014-12-15 |
2018-05-16 |
The Regents of the University of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
EP3240805A4
(en)
|
2014-12-15 |
2018-05-09 |
The Regents of the University of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
CA2970440A1
(en)
*
|
2014-12-24 |
2016-06-30 |
Ucl Business Plc |
Cell co-expressing chimeric antigen receptors binding cd19 and cd22
|
CA3197849A1
(en)
*
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
TWI718118B
(zh)
|
2015-01-16 |
2021-02-11 |
美商奇諾治療有限公司 |
針對ror1之特異性抗體及嵌合抗原受體
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
ES2869972T3
(es)
|
2015-01-26 |
2021-10-26 |
Cellectis |
Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
|
ES2789330T3
(es)
*
|
2015-01-29 |
2020-10-26 |
Univ Minnesota |
Receptores de antígeno quimérico, composiciones y métodos
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
SG11201706236SA
(en)
*
|
2015-02-06 |
2017-08-30 |
Nat Univ Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
AU2016219511B2
(en)
|
2015-02-09 |
2020-11-12 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
US20160228544A1
(en)
*
|
2015-02-11 |
2016-08-11 |
Ensysce Biosciences, Inc. |
Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Thereto
|
AU2016219785B2
(en)
|
2015-02-20 |
2021-10-28 |
Ohio State Innovation Foundation |
Bivalent antibody directed against NKG2D and tumor associated antigens
|
MA41613A
(fr)
*
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
EP3261656B1
(en)
|
2015-02-24 |
2020-08-19 |
Board of Regents, The University of Texas System |
Selection methods for genetically-modified t cells
|
AU2016222887B2
(en)
|
2015-02-24 |
2022-07-14 |
The Regents Of The University Of California |
Binding-triggered transcriptional switches and methods of use thereof
|
JP7237449B2
(ja)
*
|
2015-02-27 |
2023-03-13 |
アイセル・ジーン・セラピューティクス・エルエルシー |
血液系腫瘍を標的としたキメラ抗体受容体(CARs)の構成およびその使用方法
|
BR112017018770A2
(pt)
*
|
2015-03-02 |
2018-04-17 |
Innovative Cellular Therapeutics CO., LTD. |
redução da tolerância imunológica induzida por pd-l1
|
US10195272B2
(en)
|
2015-03-02 |
2019-02-05 |
The Nemours Foundation |
Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
|
RU2755227C2
(ru)
*
|
2015-03-05 |
2021-09-14 |
Фред Хатчинсон Кансэр Рисёч Сентер |
Иммуномодулирующие слитые белки и пути их применения
|
JP2018513123A
(ja)
|
2015-03-12 |
2018-05-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Rorガンマ阻害剤を用いてがんを治療するための方法
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
HUE049081T2
(hu)
|
2015-03-20 |
2020-09-28 |
The United States Of America As |
GP120 elleni neutralizáló antitestek és alkalmazásuk
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
ES2904573T3
(es)
|
2015-03-27 |
2022-04-05 |
Univ Southern California |
Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
|
US20190119385A1
(en)
*
|
2015-03-27 |
2019-04-25 |
University Of Southern California |
Hla-g as a novel target for car t-cell immunotherapy
|
WO2016161415A2
(en)
*
|
2015-04-02 |
2016-10-06 |
Memorial Sloan Kettering Cancer Center |
Tnfrsf14/ hvem proteins and methods of use thereof
|
CA2979732A1
(en)
|
2015-04-03 |
2016-10-06 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
HUE054435T2
(hu)
|
2015-04-06 |
2021-09-28 |
Subdomain Llc |
De novo kötõdomént tartalmazó polipeptidek és alkalmazásaik
|
US11045543B2
(en)
|
2015-04-06 |
2021-06-29 |
Cytoimmune Therapeutics, Inc. |
EGFR-directed car therapy for glioblastoma
|
JP6961490B2
(ja)
*
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Cd20療法、cd22療法、およびcd19キメラ抗原受容体(car)発現細胞との併用療法
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
EP4234685A3
(en)
|
2015-04-17 |
2023-09-06 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
US20180298068A1
(en)
|
2015-04-23 |
2018-10-18 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
RU2017140778A
(ru)
|
2015-04-25 |
2019-05-27 |
Дзе Дженерал Хоспитал Корпорейшн |
Комбинированная терапия антифугетактическим средством и противораковым средством, и композиции для лечения рака
|
WO2016176652A2
(en)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
JP6985934B2
(ja)
*
|
2015-04-29 |
2021-12-22 |
フレッド ハッチンソン キャンサー リサーチ センター |
操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用
|
CA2984180A1
(en)
*
|
2015-04-30 |
2016-11-03 |
University Of Southern California |
Secretory tnt car cell immunotherapy
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
AU2016257721B2
(en)
|
2015-05-01 |
2019-11-14 |
The Regents Of The University Of California |
Glycan-dependent immunotherapeutic molecules
|
CA2982847A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
|
KR102138209B1
(ko)
|
2015-05-06 |
2020-07-28 |
스니프르 테크놀로지스 리미티드 |
미생물 개체군 변경 및 미생물군 변형
|
CA2988854A1
(en)
|
2015-05-08 |
2016-11-17 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
US11253616B2
(en)
|
2017-09-06 |
2022-02-22 |
The Trustees Of The University Of Pennsylvania |
Small molecules for dual function positron emission tomography (PET) and cell suicide switches
|
US20200316231A1
(en)
*
|
2015-05-10 |
2020-10-08 |
The Trustees Of The University Of Pennsylvania |
Compositions And Methods For Imaging Immune Cells
|
WO2016180467A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Biontech Cell & Gene Therapies Gmbh |
Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
WO2016187216A1
(en)
*
|
2015-05-18 |
2016-11-24 |
Bluebird Bio, Inc. |
Anti-ror1 chimeric antigen receptors
|
BR112017024757A2
(pt)
|
2015-05-18 |
2018-11-13 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr utilizando proteínas de fusão
|
CN116196401A
(zh)
|
2015-05-20 |
2023-06-02 |
博德研究所 |
共有的新抗原
|
EP3298046A1
(en)
|
2015-05-20 |
2018-03-28 |
Cellectis |
Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
|
US10434153B1
(en)
|
2015-05-20 |
2019-10-08 |
Kim Leslie O'Neill |
Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
|
EP3297629A1
(en)
|
2015-05-20 |
2018-03-28 |
Novartis AG |
Pharmaceutical combination of everolimus with dactolisib
|
BR112017025120A2
(pt)
|
2015-05-28 |
2018-08-07 |
Kite Pharma Inc |
métodos de diagnóstico para terapia de células t
|
JP7121496B2
(ja)
*
|
2015-05-28 |
2022-08-18 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
癌治療で使用するためのペグ化インターロイキン-10
|
SG10201913613SA
(en)
*
|
2015-05-28 |
2020-03-30 |
Kite Pharma Inc |
Methods of conditioning patients for t cell therapy
|
CN108174607A
(zh)
|
2015-05-29 |
2018-06-15 |
朱诺治疗学股份有限公司 |
用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
|
EP3303381A1
(en)
|
2015-05-29 |
2018-04-11 |
Fred Hutchinson Cancer Research Center |
Compositions for cellular immunotherapy
|
WO2016196344A1
(en)
|
2015-05-30 |
2016-12-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
US10711064B2
(en)
|
2015-06-04 |
2020-07-14 |
University Of Southern California |
Lym-1 and Lym-2 targeted CAR cell immunotherapy
|
GB2554608B
(en)
*
|
2015-06-05 |
2022-04-06 |
Novartis Ag |
Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal
|
CN108289950B
(zh)
|
2015-06-09 |
2022-10-21 |
纪念斯隆凯特琳癌症中心 |
特异于人hla呈递的ebv潜伏膜蛋白2a肽的t细胞受体样抗体药剂
|
IL309167A
(en)
*
|
2015-06-10 |
2024-02-01 |
Immunitybio Inc |
Modified NK-92 cells for cancer treatment
|
KR20180025894A
(ko)
|
2015-06-11 |
2018-03-09 |
라이세라 코퍼레이션 |
Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
|
CN105177031B
(zh)
*
|
2015-06-12 |
2018-04-24 |
北京艺妙神州医疗科技有限公司 |
嵌合抗原受体修饰的t细胞及其用途
|
US10639329B2
(en)
|
2015-06-12 |
2020-05-05 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered T-cells
|
AU2016274989A1
(en)
*
|
2015-06-12 |
2017-11-02 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
CN115925971A
(zh)
|
2015-06-19 |
2023-04-07 |
塞巴斯蒂安·科博尔德 |
Pd-1-cd28融合蛋白及其在医学中的用途
|
EP3313872A4
(en)
|
2015-06-25 |
2019-03-20 |
iCell Gene Therapeutics LLC |
CHIMERIC ANTIGEN RECEPTORS (CARS) COMPOSITIONS AND METHOD FOR USE THEREOF
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
WO2017004252A1
(en)
|
2015-06-30 |
2017-01-05 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
|
MA42902A
(fr)
*
|
2015-07-08 |
2018-05-16 |
Univ Johns Hopkins |
Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
|
US11116795B2
(en)
*
|
2015-07-10 |
2021-09-14 |
The Trustees Of The University Of Pennsylvania |
Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
TW201708538A
(zh)
|
2015-07-21 |
2017-03-01 |
諾華公司 |
改良免疫細胞之功效及擴展之方法
|
US10493139B2
(en)
*
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
CA2992742A1
(en)
|
2015-07-28 |
2017-02-02 |
The Trustees Of The University Of Pennsylvania |
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
|
WO2017023801A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
EP3575403A1
(en)
*
|
2015-08-05 |
2019-12-04 |
Yoo Young Pharm Co., Ltd. |
Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
|
MX2018001568A
(es)
|
2015-08-07 |
2019-04-25 |
Seattle Children´S Hospital Dba Seattle Children´S Res Institute |
Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
US11286531B2
(en)
|
2015-08-11 |
2022-03-29 |
The Johns Hopkins University |
Assaying ovarian cyst fluid
|
US11352439B2
(en)
|
2015-08-13 |
2022-06-07 |
Kim Leslie O'Neill |
Macrophage CAR (MOTO-CAR) in immunotherapy
|
CN106467906B
(zh)
*
|
2015-08-20 |
2019-09-27 |
北京马力喏生物科技有限公司 |
构建体、转基因淋巴细胞及其制备方法和用途
|
US10976232B2
(en)
|
2015-08-24 |
2021-04-13 |
Gpb Scientific, Inc. |
Methods and devices for multi-step cell purification and concentration
|
CN108348551A
(zh)
*
|
2015-08-28 |
2018-07-31 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
EP3340995A4
(en)
*
|
2015-08-28 |
2019-04-03 |
The Trustees Of The University Of Pennsylvania |
METHODS AND COMPOSITIONS FOR CELLS EXPRESSING A CHIMERIC INTRACELLULAR SIGNALING MOLECULE
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
AU2016315704B2
(en)
*
|
2015-08-31 |
2022-08-11 |
Helixmith Co., Ltd |
Anti-sialyl Tn chimeric antigen receptors
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
WO2017041143A1
(en)
*
|
2015-09-11 |
2017-03-16 |
Ctm@Crc Ltd. |
Chimeric antigen receptors and uses thereof
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
AU2016324160A1
(en)
|
2015-09-18 |
2018-04-26 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Localized delivery of anti-fugetactic agent for treatment of cancer
|
EP3349767A4
(en)
*
|
2015-09-18 |
2019-03-20 |
The General Hospital Corporation Dba Massachusetts General Hospital |
T MODIFIED LYMPHOCYTES HAVING ANTICHIMIOREPULSION PROPERTIES AND USES THEREOF
|
MA42951A
(fr)
|
2015-09-22 |
2018-08-01 |
Univ Pennsylvania |
Méthode de réacheminement de lymphocytes t pour le traitement d'une infection par le vih
|
ES2768957T3
(es)
|
2015-09-24 |
2020-06-24 |
Abvitro Llc |
Composiciones de anticuerpos contra el VIH y métodos de uso
|
US10928392B2
(en)
|
2015-09-25 |
2021-02-23 |
Abvitro Llc |
High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
|
EP3355937A4
(en)
|
2015-09-28 |
2019-04-17 |
Regents of the University of Minnesota |
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
|
WO2017058752A1
(en)
*
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
JP6985256B2
(ja)
*
|
2015-10-06 |
2021-12-22 |
シティ・オブ・ホープCity of Hope |
Pscaを標的とするキメラ抗原レセプター
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
EP3360961B1
(en)
*
|
2015-10-08 |
2023-11-22 |
National University Corporation Tokai National Higher Education and Research System |
Method for preparing genetically-modified t cells which express chimeric antigen receptor
|
WO2017059796A1
(en)
|
2015-10-08 |
2017-04-13 |
Shanghai Sidansai Biotechnology Co., Ltd |
Activation and expansion of t cells
|
CN105153315B
(zh)
*
|
2015-10-09 |
2019-04-02 |
重庆精准生物技术有限公司 |
免疫抑制受体联合肿瘤抗原嵌合受体及其应用
|
CN108474040B
(zh)
*
|
2015-10-09 |
2023-05-16 |
夸登特健康公司 |
使用无细胞dna的基于群体的治疗推荐
|
WO2017062820A1
(en)
*
|
2015-10-09 |
2017-04-13 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
CN105924530B
(zh)
*
|
2015-10-13 |
2019-08-06 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、car20-nkt细胞及其制备方法和应用
|
CN106755023A
(zh)
*
|
2015-10-15 |
2017-05-31 |
中国人民解放军军事医学科学院附属医院 |
带安全开关的嵌合抗原受体免疫细胞及其制备方法与应用
|
EP3362569B1
(en)
|
2015-10-16 |
2021-09-01 |
Ludwig-Maximilians-Universität München |
Cxcr6-transduced t cells for targeted tumor therapy
|
EP3362472B1
(en)
|
2015-10-16 |
2023-08-30 |
The Trustees of Columbia University in the City of New York |
Compositions and methods for inhibition of lineage specific antigens
|
KR20180066237A
(ko)
|
2015-10-19 |
2018-06-18 |
유니버시티 오브 매사추세츠 |
항-암 및 항-염증 치료제 및 이의 방법
|
TW202317758A
(zh)
|
2015-10-20 |
2023-05-01 |
美商凱特製藥公司 |
製備用於t細胞治療之t細胞的方法
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
CA3002742A1
(en)
|
2015-10-22 |
2017-04-27 |
Juno Therapeutics Gmbh |
Methods, kits, agents and apparatuses for transduction
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
CN105132445B
(zh)
*
|
2015-10-23 |
2018-10-02 |
马健颖 |
一种特异识别肿瘤细胞的受体蛋白、t淋巴细胞及nk细胞
|
CN108883170A
(zh)
*
|
2015-10-23 |
2018-11-23 |
索伦托治疗有限公司 |
可程序化的通用细胞受体及其使用方法
|
WO2017075147A1
(en)
|
2015-10-27 |
2017-05-04 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
MA44314A
(fr)
*
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
CN105331585A
(zh)
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
CN105384826A
(zh)
*
|
2015-11-19 |
2016-03-09 |
广州熙帝生物科技有限公司 |
表达嵌合抗原受体的脐血有核细胞及其应用
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
SG11201803493UA
(en)
*
|
2015-11-27 |
2018-05-30 |
Cartherics Pty Ltd |
Genetically modified cells and uses thereof
|
WO2017096327A2
(en)
|
2015-12-03 |
2017-06-08 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against cell therapies
|
US20180355014A1
(en)
|
2015-12-03 |
2018-12-13 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
CN108699557A
(zh)
|
2015-12-04 |
2018-10-23 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
ES2901795T3
(es)
|
2015-12-04 |
2022-03-23 |
Juno Therapeutics Inc |
Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular
|
EP3384013A4
(en)
*
|
2015-12-04 |
2019-07-10 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
T-CELLS SPECIFIC TO ANTIGEN TO INDUCE IMMUNE TOLERANCE
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
US10953003B2
(en)
|
2015-12-14 |
2021-03-23 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
EP3389652B1
(en)
|
2015-12-14 |
2022-09-28 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
ES2935834T3
(es)
|
2015-12-22 |
2023-03-10 |
X4 Pharmaceuticals Inc |
Métodos para tratar enfermedad de inmunodeficiencia
|
JP7082055B2
(ja)
|
2015-12-22 |
2022-06-07 |
ノバルティス アーゲー |
抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体
|
ES2944597T3
(es)
|
2015-12-30 |
2023-06-22 |
Novartis Ag |
Terapias con células efectoras inmunitarias de eficacia mejorada
|
GB201600328D0
(en)
|
2016-01-08 |
2016-02-24 |
Univ Oslo Hf |
Anti-CD37 chimeric antigen receptors and immune cells expressing them
|
SG11201804038VA
(en)
|
2016-01-08 |
2018-06-28 |
Univ California |
Conditionally active heterodimeric polypeptides and methods of use thereof
|
CN105950645A
(zh)
*
|
2016-01-11 |
2016-09-21 |
灏灵赛奥(天津)生物科技有限公司 |
Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
|
US11505599B2
(en)
|
2016-01-14 |
2022-11-22 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like antibodies specific for Foxp3-derived peptides
|
WO2017123911A1
(en)
*
|
2016-01-15 |
2017-07-20 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating cancer
|
DK3405490T3
(da)
|
2016-01-21 |
2022-01-10 |
Pfizer |
Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
|
WO2017125830A1
(en)
|
2016-01-21 |
2017-07-27 |
Pfizer Inc. |
Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
|
CN105567640A
(zh)
*
|
2016-01-27 |
2016-05-11 |
苏州佰通生物科技有限公司 |
一种嵌合抗原受体脂肪干细胞及其制备方法
|
US10179919B2
(en)
|
2016-02-23 |
2019-01-15 |
Immune Design Corp. |
Multigenome retroviral vector preparations and methods and systems for producing and using same
|
US11542486B2
(en)
|
2016-03-02 |
2023-01-03 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
CN109153714A
(zh)
|
2016-03-04 |
2019-01-04 |
诺华股份有限公司 |
表达多重嵌合抗原受体(car)分子的细胞及其用途
|
US10563172B2
(en)
*
|
2016-03-14 |
2020-02-18 |
Wisconsin Alumni Research Foundation |
Methods of T cell expansion and activation
|
MA43758A
(fr)
|
2016-03-16 |
2018-11-28 |
Yuan Ji |
Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
|
US20190355459A1
(en)
|
2016-03-16 |
2019-11-21 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
BR112018068314A2
(pt)
*
|
2016-03-17 |
2019-01-15 |
Univ Yamaguchi |
célula imunocompetente e vetor de expressão que expressam fatores regulatórios de função imunológica
|
KR102366611B1
(ko)
|
2016-03-18 |
2022-02-23 |
프레드 헛친슨 켄서 리서치 센터 |
Cd20 면역요법을 위한 조성물 및 방법
|
KR20190021200A
(ko)
|
2016-03-22 |
2019-03-05 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
독성을 예방 또는 경감시키기 위한 조기 개재 방법
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
CN109641008B
(zh)
|
2016-04-01 |
2021-03-23 |
凯德药业股份有限公司 |
嵌合受体及其方法和用途
|
US10654934B2
(en)
|
2016-04-01 |
2020-05-19 |
Innovative Cellular Therapeutics CO., LTD. |
Use of chimeric antigen receptor modified cells to treat cancer
|
TWI761831B
(zh)
|
2016-04-01 |
2022-04-21 |
美商凱特製藥公司 |
嵌合抗原受體(car)和t細胞受體(tcr)及彼等之用途
|
IL261941B2
(en)
|
2016-04-01 |
2023-11-01 |
Kite Pharma Inc |
Chimeric antigen and T cell receptors and methods of use
|
CN113082201A
(zh)
|
2016-04-01 |
2021-07-09 |
上海斯丹赛生物技术有限公司 |
刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
|
CR20180518A
(es)
|
2016-04-01 |
2019-04-25 |
Kite Pharma Inc |
Receptores quiméricos de flt3 y métodos de uso de los mismos
|
CN108778312B
(zh)
|
2016-04-08 |
2022-07-15 |
爱默蕾大学 |
使用基于细胞的疗法治疗癌症和传染病的方法
|
CN109153722A
(zh)
|
2016-04-08 |
2019-01-04 |
X4 制药有限公司 |
用于治疗癌症的方法
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
CN106399255B
(zh)
*
|
2016-04-13 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
Pd-1 car-t细胞及其制备方法和应用
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
JP2019521643A
(ja)
|
2016-04-15 |
2019-08-08 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Cd80バリアント免疫調節タンパク質およびその使用
|
US20230071283A1
(en)
|
2016-04-15 |
2023-03-09 |
Aimee S. Payne |
Compositions and methods for selective protein expression
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
CN105907719B
(zh)
*
|
2016-04-18 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
Anti ROBO1 CAR-T细胞及其制备和应用
|
EP3445407B1
(en)
*
|
2016-04-22 |
2022-12-14 |
CRAGE medical Co., Limited |
Compositions and methods of cellular immunotherapy
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
IL302641A
(en)
|
2016-05-06 |
2023-07-01 |
Juno Therapeutics Inc |
Genetically engineered cells and methods for their preparation
|
US11261223B2
(en)
*
|
2016-05-11 |
2022-03-01 |
The University Of Chicago |
Methods of treating cancers with CT45 targeted therapies
|
ES2901215T3
(es)
|
2016-05-27 |
2022-03-21 |
Aadigen Llc |
Péptidos y nanopartículas para la liberación intracelular de moléculas de edición del genoma
|
JP2019519529A
(ja)
*
|
2016-05-27 |
2019-07-11 |
アメリカ合衆国 |
Flt3特異的なキメラ抗原受容体及びそれを使用する方法
|
CN105837693A
(zh)
*
|
2016-05-30 |
2016-08-10 |
李斯文 |
一种基于bcma的抗原嵌合受体及其制备方法和应用
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
MX2018014991A
(es)
|
2016-06-03 |
2019-08-29 |
Memorial Sloan Kettering Cancer Center |
Terapias adoptivas de celulas como opciones de tratamiento temprano.
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
US11390658B2
(en)
|
2016-06-06 |
2022-07-19 |
St. Jude Children's Research Hospital |
Anti-CD7 chimeric antigen receptor and method of use thereof
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
CN109562170B
(zh)
|
2016-06-08 |
2023-01-13 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
AU2017279539A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-B7-H3 antibodies and antibody drug conjugates
|
PL3458479T3
(pl)
|
2016-06-08 |
2021-07-26 |
Abbvie Inc. |
Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
|
JP2019517267A
(ja)
|
2016-06-08 |
2019-06-24 |
イントレキソン コーポレーション |
Cd33特異的キメラ抗原受容体
|
CN109562168A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
JP2019521973A
(ja)
|
2016-06-08 |
2019-08-08 |
アッヴィ・インコーポレイテッド |
抗bh7−h3抗体及び抗体薬物コンジュゲート
|
CN116554168A
(zh)
|
2016-06-21 |
2023-08-08 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
JP7084624B2
(ja)
|
2016-06-21 |
2022-06-15 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
EP3474867A4
(en)
|
2016-06-24 |
2020-05-20 |
iCell Gene Therapeutics LLC |
CHIMERIC ANTIGEN (CAR) RECEPTORS, COMPOSITIONS AND RELATED METHODS
|
CN106117367B
(zh)
*
|
2016-06-24 |
2020-02-11 |
安徽未名细胞治疗有限公司 |
一种her-3特异性嵌合抗原受体及其应用
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
EP3475446A1
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
JP7175769B2
(ja)
|
2016-06-30 |
2022-11-21 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
改善された養子t細胞療法
|
KR102223822B1
(ko)
|
2016-07-12 |
2021-03-11 |
카이트 파마 인코포레이티드 |
항원 결합 분자 및 그의 사용 방법
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
CN110461315A
(zh)
|
2016-07-15 |
2019-11-15 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
CN109477114A
(zh)
*
|
2016-07-18 |
2019-03-15 |
赫利克斯生物药品公司 |
治疗癌症的针对癌胚抗原相关细胞粘附分子6的car免疫细胞
|
CA3031542A1
(en)
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Cd229 car t cells and methods of use thereof
|
US11384156B2
(en)
|
2016-07-25 |
2022-07-12 |
The Nemours Foundation |
Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
|
CN110214150A
(zh)
|
2016-07-28 |
2019-09-06 |
诺华股份有限公司 |
嵌合抗原受体和pd-1抑制剂的组合疗法
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
US11421287B2
(en)
|
2016-07-29 |
2022-08-23 |
Juno Therapeutics, Inc. |
Methods for assessing the presence or absence of replication competent virus
|
JP7295795B2
(ja)
|
2016-07-29 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
免疫調節ポリペプチドならびに関連する組成物および方法
|
KR102553195B1
(ko)
|
2016-07-29 |
2023-07-07 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항-cd19 항체에 대한 항-이디오타입 항체
|
CA3032581A1
(en)
|
2016-08-01 |
2018-02-08 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
CN112481217A
(zh)
|
2016-09-01 |
2021-03-12 |
嵌合体生物工程公司 |
Gold优化的car t-细胞
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
CN109843922B
(zh)
|
2016-09-02 |
2023-10-03 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
CA3039136A1
(en)
|
2016-09-02 |
2018-03-08 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
US20190211292A1
(en)
|
2016-09-12 |
2019-07-11 |
Juno Therapeutics, Inc. |
Perfusion bioreactor bag assemblies
|
JP6908710B2
(ja)
|
2016-09-21 |
2021-07-28 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
ケモカイン受容体ccr4を標的にするキメラ抗原受容体(car)およびその使用
|
WO2018057904A1
(en)
*
|
2016-09-23 |
2018-03-29 |
University Of Southern California |
Chimeric antigen receptors and compositions and methods of use thereof
|
CA3038897A1
(en)
|
2016-09-28 |
2018-04-05 |
Atossa Genetics Inc. |
Methods of adoptive cell therapy
|
TWI828334B
(zh)
|
2016-09-28 |
2024-01-01 |
美商凱特製藥公司 |
抗原結合分子類和使用彼等之方法
|
CA3037086A1
(en)
|
2016-10-03 |
2018-04-12 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
PL3445787T3
(pl)
|
2016-10-07 |
2021-05-31 |
TCR2 Therapeutics Inc. |
Kompozycje i sposoby reprogramowania receptorów limfocytów t przy użyciu białek fuzyjnych
|
AU2017341047A1
(en)
|
2016-10-07 |
2019-05-02 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
CN107151654B
(zh)
*
|
2016-10-11 |
2020-05-05 |
深圳宾德生物技术有限公司 |
一种人源t淋巴细胞的培养基及其制备方法和应用
|
CN107936120B
(zh)
*
|
2016-10-13 |
2021-03-09 |
上海赛比曼生物科技有限公司 |
Cd19靶向性的嵌合抗原受体及其制法和应用
|
CN110381963A
(zh)
|
2016-10-13 |
2019-10-25 |
朱诺治疗学股份有限公司 |
涉及色氨酸代谢途径调节剂的免疫治疗方法和组合物
|
GB2605540B
(en)
|
2016-10-18 |
2022-12-21 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
KR102613430B1
(ko)
|
2016-10-19 |
2023-12-18 |
더 스크립스 리서치 인스티튜트 |
인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
|
EP3528851B1
(en)
|
2016-10-20 |
2022-04-27 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
SG11201903407XA
(en)
|
2016-10-20 |
2019-05-30 |
Alpine Immune Sciences Inc |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
MA46783A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de type thérapie cellulaire t et inhibiteur de btk
|
WO2018093591A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
US11261428B2
(en)
|
2018-03-15 |
2022-03-01 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
CN110268049A
(zh)
|
2016-11-22 |
2019-09-20 |
新加坡国立大学 |
用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
|
US10441584B2
(en)
|
2016-11-23 |
2019-10-15 |
Novartis Ag |
Methods of enhancing immune response
|
AU2017368320A1
(en)
*
|
2016-12-02 |
2019-05-02 |
Cartesian Therapeutics, Inc. |
Cancer immuno therapy with highly enriched CD8+ chimeric antigen receptor T cells
|
JP2020511462A
(ja)
|
2016-12-03 |
2020-04-16 |
ジュノー セラピューティクス インコーポレイテッド |
キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物
|
AU2017368332A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for modulation of CAR-T cells
|
MX2019006286A
(es)
|
2016-12-03 |
2020-02-07 |
Juno Therapeutics Inc |
Metodos para determinar la dosificacion en la terapia celular.
|
KR20190098747A
(ko)
|
2016-12-05 |
2019-08-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료법을 위한 조작된 세포의 제조방법
|
CN108165568B
(zh)
*
|
2016-12-07 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
一种培养CD19CAR-iNKT细胞方法及用途
|
CN107058315B
(zh)
*
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
|
AU2017375630B2
(en)
|
2016-12-12 |
2023-12-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
CN108218994A
(zh)
*
|
2016-12-14 |
2018-06-29 |
上海恒润达生生物科技有限公司 |
一种方法培养t记忆干细胞
|
US11278570B2
(en)
|
2016-12-16 |
2022-03-22 |
B-Mogen Biotechnologies, Inc. |
Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
|
CA3047313A1
(en)
|
2016-12-16 |
2018-06-21 |
B-Mogen Biotechnologies, Inc. |
Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
|
CN108276493B
(zh)
*
|
2016-12-30 |
2023-11-14 |
南京传奇生物科技有限公司 |
一种嵌合抗原受体及其应用
|
CA3048312A1
(en)
|
2017-01-01 |
2018-07-05 |
Chi-Yu Gregory Lee |
Rp215 chimeric antigen receptor construct and methods of making and using same
|
CN116120454A
(zh)
|
2017-01-05 |
2023-05-16 |
上海煦顼技术有限公司 |
人源化抗cd19抗体及其与嵌合抗原受体的用途
|
WO2018129270A1
(en)
|
2017-01-05 |
2018-07-12 |
Fred Hutchinson Cancer Research Center |
Systems and methods to improve vaccine efficacy
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
EP3565586A1
(en)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
EP3565888A1
(en)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
EP3346001A1
(en)
*
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
CN108285920A
(zh)
*
|
2017-01-09 |
2018-07-17 |
上海恒润达生生物科技有限公司 |
一种体内检测cart细胞表达的技术及其用途
|
EP3568414A1
(en)
|
2017-01-10 |
2019-11-20 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
GB201700553D0
(en)
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
EP3568416A4
(en)
*
|
2017-01-13 |
2020-07-08 |
Celdara Medical, LLC |
TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS
|
JP2020505034A
(ja)
|
2017-01-20 |
2020-02-20 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞表面コンジュゲートならびに関連する細胞組成物および方法
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
CN108342363B
(zh)
*
|
2017-01-25 |
2021-02-12 |
北京马力喏生物科技有限公司 |
共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
RU2674894C2
(ru)
*
|
2017-01-30 |
2018-12-13 |
Общество с ограниченной ответственностью "ПЛАНТА" |
Новые люциферазы и способы их использования
|
WO2018144597A1
(en)
*
|
2017-01-31 |
2018-08-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods of sensitizing cancer cells to immune cell killing
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
CN110612119A
(zh)
|
2017-02-07 |
2019-12-24 |
西雅图儿童医院(Dba西雅图儿童研究所) |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
KR20230119735A
(ko)
|
2017-02-12 |
2023-08-16 |
바이오엔테크 유에스 인크. |
Hla 기반 방법 및 조성물, 및 이들의 용도
|
AR110979A1
(es)
|
2017-02-14 |
2019-05-22 |
Kite Pharma Inc |
Moléculas de unión a cd70 y métodos de uso de las mismas
|
EP4269594A3
(en)
|
2017-02-17 |
2023-12-20 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
US11597911B2
(en)
|
2017-02-27 |
2023-03-07 |
Life Technologies Corporation |
Expansion of populations of T cells by the use of modified serum free media
|
JP7228522B2
(ja)
|
2017-02-27 |
2023-02-24 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法における投薬に関する組成物、製造物品、および方法
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
EP3589295A4
(en)
|
2017-02-28 |
2020-11-04 |
Endocyte, Inc. |
COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
KR20200010181A
(ko)
*
|
2017-03-03 |
2020-01-30 |
옵시디안 테라퓨틱스, 인크. |
Cd19 조성물 및 면역치료를 위한 방법
|
SG11201907889YA
(en)
|
2017-03-03 |
2019-09-27 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
WO2018170188A2
(en)
|
2017-03-14 |
2018-09-20 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
EP3596115A1
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
BR112019018747A2
(pt)
|
2017-03-16 |
2020-05-05 |
Alpine Immune Sciences Inc |
proteínas imunomoduladoras variantes de cd80 e usos das mesmas
|
CA3053804A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
AU2018236461A1
(en)
|
2017-03-17 |
2019-09-19 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
CN110832075A
(zh)
|
2017-03-22 |
2020-02-21 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
JP2020515542A
(ja)
|
2017-03-23 |
2020-05-28 |
ザ ジェネラル ホスピタル コーポレイション |
Cxcr4/cxcr7の遮断およびヒトパピローマウイルス関連疾患の治療
|
EP3601356A1
(en)
*
|
2017-03-24 |
2020-02-05 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
JP7270253B2
(ja)
|
2017-03-27 |
2023-05-10 |
ナショナル ユニヴァーシティ オブ シンガポール |
ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株
|
CN110636851B
(zh)
|
2017-03-27 |
2023-11-03 |
新加坡国立大学 |
截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
AU2018243664B2
(en)
|
2017-03-31 |
2024-02-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling
|
SG11201907744QA
(en)
|
2017-04-01 |
2019-09-27 |
Avm Biotechnology Llc |
Replacement of cytotoxic preconditioning before cellular immunotherapy
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
KR20220144888A
(ko)
|
2017-04-03 |
2022-10-27 |
카이트 파마 인코포레이티드 |
최적화된 다기능 t 세포를 포함하는 키메라 수용체 t 세포를 사용하는 치료
|
EP3607319A1
(en)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
EP3610035A4
(en)
|
2017-04-14 |
2021-06-09 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND PROCEDURES FOR TEMPORARY GENE THERAPY WITH IMPROVED STABILITY
|
MA54103A
(fr)
|
2017-04-14 |
2021-09-15 |
Juno Therapeutics Inc |
Procédés d'évaluation de la glycosylation de surface cellulaire
|
CN108727497A
(zh)
*
|
2017-04-17 |
2018-11-02 |
沈阳美达博生物科技有限公司 |
一种cd19抗体及其应用
|
MX2019012398A
(es)
|
2017-04-18 |
2020-09-25 |
Broad Inst Inc |
Composiciones para detectar secreciones y metodos de uso.
|
WO2018195175A1
(en)
|
2017-04-18 |
2018-10-25 |
FUJIFILM Cellular Dynamics, Inc. |
Antigen-specific immune effector cells
|
WO2018195339A1
(en)
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
SG11201909710XA
(en)
|
2017-04-21 |
2019-11-28 |
Kyn Therapeutics |
Indole ahr inhibitors and uses thereof
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
JP7339160B2
(ja)
|
2017-04-27 |
2023-09-05 |
ジュノ セラピューティクス ゲーエムベーハー |
オリゴマー粒子試薬およびその使用方法
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
PT3618842T
(pt)
|
2017-05-01 |
2024-01-12 |
Juno Therapeutics Inc |
Combinação de uma terapia celular e de um composto imunomodulador
|
SG11201910127XA
(en)
*
|
2017-05-02 |
2019-11-28 |
Chongqing Prec Biotech Company Limited |
Chimeric antigen receptor against human cd19 antigen and its application
|
CN107226867B
(zh)
*
|
2017-07-25 |
2018-02-06 |
重庆精准生物技术有限公司 |
抗人cd19抗原的嵌合抗原受体及其应用
|
JP7349365B2
(ja)
*
|
2017-05-10 |
2023-09-22 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
EP3406733A1
(en)
|
2017-05-24 |
2018-11-28 |
SIB Swiss Institute of Bioinformatics |
Kinase mutants and uses thereof
|
CN110891567B
(zh)
|
2017-05-24 |
2024-01-09 |
效应治疗股份有限公司 |
用于改善的抗肿瘤免疫应答的组合物和方法
|
EP3630807A1
(en)
|
2017-05-25 |
2020-04-08 |
Leidos, Inc. |
Pd-1 and ctla-4 dual inhibitor peptides
|
KR20210118479A
(ko)
|
2017-05-26 |
2021-09-30 |
카이트 파마 인코포레이티드 |
배아 중간엽 전구 세포를 제조하고 사용하는 방법
|
CN110770348B
(zh)
|
2017-06-01 |
2023-12-15 |
浙江煦顼技术有限公司 |
嵌合抗原受体细胞的制备及其用途
|
US20200098480A1
(en)
*
|
2017-06-02 |
2020-03-26 |
Mayo Foundation For Medical Education And Research |
System and method for providing clinical outcomes driven expertise for disease treatment
|
EP3630132A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
US11740231B2
(en)
|
2017-06-02 |
2023-08-29 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
WO2018234370A1
(en)
|
2017-06-20 |
2018-12-27 |
Institut Curie |
DEFECTIVE IMMUNE CELLS AGAINST SUV39H1
|
US10233226B2
(en)
|
2017-06-21 |
2019-03-19 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for chimeric antigen receptor targeting cancer cells
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
CN111373260A
(zh)
|
2017-06-22 |
2020-07-03 |
得克萨斯大学体系董事会 |
产生调节性免疫细胞的方法及其用途
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
AU2018290856A1
(en)
|
2017-06-28 |
2020-01-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
|
US20220225597A1
(en)
|
2017-06-29 |
2022-07-21 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
JP2020530277A
(ja)
|
2017-06-30 |
2020-10-22 |
セレクティスCellectis |
反復投与のための細胞免疫療法
|
CN111511375A
(zh)
|
2017-06-30 |
2020-08-07 |
因提玛生物科学公司 |
用于基因治疗的腺相关病毒载体
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
CN107287164A
(zh)
*
|
2017-07-07 |
2017-10-24 |
青岛协和华美医学诊断技术有限公司 |
靶向cd19的嵌合抗原受体t细胞、制备方法及应用
|
CN107365798B
(zh)
*
|
2017-07-13 |
2020-07-14 |
山东省齐鲁细胞治疗工程技术有限公司 |
一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
|
MA49652A
(fr)
|
2017-07-17 |
2020-05-27 |
Janssen Biotech Inc |
Régions de liaison à un antigène dirigées contre les domaines de la fibronectine de type iii et leurs procédés d'utilisation
|
KR20200064060A
(ko)
|
2017-07-29 |
2020-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 세포 증폭용 시약
|
JP7237926B2
(ja)
|
2017-07-31 |
2023-03-13 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd19/cd20免疫療法によりがんを処置するための組成物および方法
|
CA3072195A1
(en)
|
2017-08-07 |
2019-04-04 |
The Johns Hopkins University |
Methods and materials for assessing and treating cancer
|
MX2020001490A
(es)
|
2017-08-09 |
2020-08-06 |
Juno Therapeutics Inc |
Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
|
AU2018313952A1
(en)
|
2017-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
US11648269B2
(en)
|
2017-08-10 |
2023-05-16 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
|
JP7269917B2
(ja)
|
2017-08-17 |
2023-05-09 |
イケナ オンコロジー, インコーポレイテッド |
Ahr阻害剤およびその使用
|
AU2018323875A1
(en)
|
2017-09-01 |
2020-04-23 |
Gpb Scientific, Inc. |
Methods for preparing therapeutically active cells using microfluidics
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
US20200292526A1
(en)
|
2017-09-07 |
2020-09-17 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
CN107557337B
(zh)
*
|
2017-09-15 |
2020-06-26 |
山东兴瑞生物科技有限公司 |
一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用
|
EP3681991A1
(en)
|
2017-09-15 |
2020-07-22 |
Life Technologies Corporation |
Compositions and methods for culturing and expanding cells
|
JP2020537635A
(ja)
|
2017-09-15 |
2020-12-24 |
カイト ファーマ インコーポレイテッドKite Pharma, Inc |
継続管理及び継続識別による生体サンプル追跡を用いた患者固有の免疫療法手順を実施する方法及びシステム
|
MX2020002901A
(es)
|
2017-09-19 |
2020-07-22 |
Massachusetts Inst Technology |
Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
|
AU2018338418A1
(en)
*
|
2017-09-19 |
2020-04-09 |
Cdrd Ventures Inc. |
Anti-HLA-A2 antibodies and methods of using the same
|
EP3684822A4
(en)
|
2017-09-20 |
2021-06-16 |
The University of British Columbia |
NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
WO2019060746A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
SYSTEMS, METHODS, AND COMPOSITIONS FOR THE TARGETED EDITING OF NUCLEIC ACIDS
|
US11623932B2
(en)
|
2017-09-22 |
2023-04-11 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US20190092818A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
Chimeric polypeptides and uses thereof
|
WO2019060713A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
ANTIGEN-BINDING MOLECULES AND METHODS OF USE THEREOF
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US11559549B2
(en)
*
|
2017-09-26 |
2023-01-24 |
Longwood University |
PD1-specific chimeric antigen receptor as an immunotherapy
|
CN109554349B
(zh)
*
|
2017-09-27 |
2022-06-24 |
亘喜生物科技(上海)有限公司 |
Pd-1基因表达沉默的工程化免疫细胞
|
TWI731268B
(zh)
*
|
2017-09-29 |
2021-06-21 |
財團法人國家衛生研究院 |
可增強抗腫瘤與抗病毒t細胞存活與其功能性之方法與組合物
|
SG11202002728VA
(en)
|
2017-10-03 |
2020-04-29 |
Juno Therapeutics Inc |
Hpv-specific binding molecules
|
EP3694875A1
(en)
|
2017-10-09 |
2020-08-19 |
Wisconsin Alumni Research Foundation |
Antibodies targeting glioblastoma stem-like cells and methods of use thereof
|
US11753458B2
(en)
|
2017-10-10 |
2023-09-12 |
Alpine Immune Sciences, Inc. |
CTLA-4 variant immunomodulatory proteins and uses thereof
|
WO2019079564A1
(en)
|
2017-10-18 |
2019-04-25 |
Kite Pharma, Inc. |
METHODS OF DELIVERY OF CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
|
CN111712515A
(zh)
|
2017-10-18 |
2020-09-25 |
高山免疫科学股份有限公司 |
变体icos配体免疫调节蛋白及相关组合物和方法
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
CN109694854B
(zh)
*
|
2017-10-20 |
2023-11-21 |
亘喜生物科技(上海)有限公司 |
通用型嵌合抗原受体t细胞制备技术
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
WO2019084234A1
(en)
*
|
2017-10-26 |
2019-05-02 |
St. Jude Childen's Research Hospital, Inc. |
METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
|
WO2019084427A1
(en)
|
2017-10-27 |
2019-05-02 |
Kite Pharma, Inc. |
T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
EP3703750A1
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
AU2018358250A1
(en)
|
2017-11-01 |
2020-05-14 |
Editas Medicine, Inc. |
Methods, compositions and components for CRISPR-CAS9 editing of TGFBR2 in T cells for immunotherapy
|
CA3084514A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
AU2018360031A1
(en)
|
2017-11-03 |
2020-05-21 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-ROR1 immunotherapy
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン,インコーポレイテッド |
免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素
|
BR112020008812A2
(pt)
|
2017-11-06 |
2020-10-27 |
Juno Therapeutics Inc |
combinação de terapia celular e um inibidor de gama secretase
|
KR20200085780A
(ko)
*
|
2017-11-07 |
2020-07-15 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
암의 치료에서 car-t 또는 car-nk 세포를 사용한 lilrb4 표적화
|
KR20200080270A
(ko)
|
2017-11-10 |
2020-07-06 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
종양 항원을 타겟으로 하는 키메릭 항원 수용체
|
WO2019094835A1
(en)
|
2017-11-10 |
2019-05-16 |
Juno Therapeutics, Inc. |
Closed-system cryogenic vessels
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
BR112020009136A2
(pt)
|
2017-11-14 |
2020-10-13 |
Arcellx, Inc. |
polipeptídeos que contêm domínio d e usos dos mesmos
|
JP7356435B2
(ja)
|
2017-11-14 |
2023-10-04 |
アーセルクス インコーポレイテッド |
多機能性免疫細胞療法
|
TW201922774A
(zh)
|
2017-11-15 |
2019-06-16 |
瑞士商諾華公司 |
標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法
|
WO2019099707A1
(en)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
EP3714041A1
(en)
*
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
CN109837244A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用
|
KR20200096253A
(ko)
|
2017-11-30 |
2020-08-11 |
노파르티스 아게 |
Bcma-표적화 키메라 항원 수용체, 및 이의 용도
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
JP7409669B2
(ja)
*
|
2017-12-04 |
2024-01-09 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ オクラホマ |
抗dclk1抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法
|
JP2021505168A
(ja)
|
2017-12-08 |
2021-02-18 |
ジュノー セラピューティクス インコーポレイテッド |
操作されたt細胞の組成物を製造するための方法
|
MA51105A
(fr)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics Inc |
Formulation de milieux sans sérum pour la culture de cellules et ses procédés d'utilisation
|
AU2018379094A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
KR20200110745A
(ko)
|
2017-12-15 |
2020-09-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항 - cct5 결합 분자 및 이의 사용 방법
|
US11661439B2
(en)
|
2017-12-17 |
2023-05-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide hydrogels and use thereof
|
WO2019126186A1
(en)
|
2017-12-18 |
2019-06-27 |
Neon Therapeutics, Inc. |
Neoantigens and uses thereof
|
CN108018312B
(zh)
*
|
2017-12-20 |
2019-09-10 |
上海优卡迪生物医药科技有限公司 |
一种t淋巴细胞白血病的car-t治疗载体及其构建方法和应用
|
CN111566120B
(zh)
|
2017-12-20 |
2023-09-29 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
WO2019133531A1
(en)
|
2017-12-26 |
2019-07-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
CN109970866B
(zh)
*
|
2017-12-28 |
2022-10-04 |
上海细胞治疗研究院 |
一种cd28双向激活共刺激分子受体及其用途
|
CN109971712B
(zh)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
|
CN109970864A
(zh)
*
|
2017-12-28 |
2019-07-05 |
上海细胞治疗研究院 |
一种双向激活共刺激分子受体及其用途
|
AU2019205315A1
(en)
*
|
2018-01-05 |
2020-07-16 |
Maxcyte, Inc. |
Chronic car treatment for cancer
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
US11919937B2
(en)
|
2018-01-09 |
2024-03-05 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
US10561686B2
(en)
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
US20220265708A1
(en)
*
|
2018-01-11 |
2022-08-25 |
Innovative Cellular Therapeutics, Inc. |
Modified Cell Expansion and Uses Thereof
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
US20210023134A1
(en)
|
2018-01-15 |
2021-01-28 |
Pfizer Inc. |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
|
TW201940182A
(zh)
|
2018-01-22 |
2019-10-16 |
美商安德賽特公司 |
Car t 細胞之使用方法
|
SG11202006832YA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
KR102115236B1
(ko)
*
|
2018-01-29 |
2020-05-27 |
(주)에스엠티바이오 |
췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
|
WO2019152743A1
(en)
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
US11535903B2
(en)
|
2018-01-31 |
2022-12-27 |
Juno Therapeutics, Inc. |
Methods and reagents for assessing the presence or absence of replication competent virus
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
US20200390814A1
(en)
|
2018-02-02 |
2020-12-17 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dna-chimeric antigen receptor t cells for immunotherapy
|
US20210087511A1
(en)
*
|
2018-02-09 |
2021-03-25 |
Global Life Sciences Solutions Usa Llc |
Bioprocessing methods for cell therapy
|
US20230183313A1
(en)
*
|
2018-02-11 |
2023-06-15 |
Jiangsu Hengrui Medicine Co., Ltd. |
Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
|
CN110157677A
(zh)
*
|
2018-02-12 |
2019-08-23 |
深圳宾德生物技术有限公司 |
一种靶向性t淋巴细胞及其制备方法和应用
|
WO2019157516A1
(en)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Combination therapies
|
TWI707849B
(zh)
|
2018-02-13 |
2020-10-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
US20200377609A1
(en)
|
2018-02-14 |
2020-12-03 |
Kite Pharma, Inc. |
Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
|
CN112534044A
(zh)
|
2018-02-16 |
2021-03-19 |
凯德药业股份有限公司 |
经修饰的多能干细胞及制备和使用方法
|
KR20200144093A
(ko)
|
2018-02-17 |
2020-12-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
막 단백질 전달을 위한 조성물 및 방법
|
KR20200130709A
(ko)
|
2018-03-06 |
2020-11-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
전립선-특이 막 항원 car 및 이의 사용 방법
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
WO2019175328A1
(en)
|
2018-03-14 |
2019-09-19 |
Imba - Institut Für Molekulare Biotechnologie Gmbh |
Bh4pathwayactivationandusethereoffortreatingcancer
|
BR112020018658A2
(pt)
|
2018-03-15 |
2020-12-29 |
KSQ Therapeutics, Inc. |
Composições de regulação gênica e métodos para imu-noterapia aprimorada
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
KR20210029707A
(ko)
|
2018-04-05 |
2021-03-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
JP7296398B2
(ja)
|
2018-04-06 |
2023-06-22 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
3’3’-環状ジヌクレオチド
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
KR20210018797A
(ko)
|
2018-04-10 |
2021-02-18 |
암젠 인크 |
Dll3에 대한 키메라 수용체 및 이의 사용 방법
|
TWI723374B
(zh)
|
2018-04-12 |
2021-04-01 |
美商凱特製藥公司 |
利用腫瘤微環境之特性之嵌合受體t細胞治療
|
WO2019200252A1
(en)
|
2018-04-13 |
2019-10-17 |
The Johns Hopkins University |
Non-invasive detection of response to immunotherapy
|
WO2019200250A1
(en)
|
2018-04-13 |
2019-10-17 |
Velculescu Victor E |
Non-invasive detection of response to a targeted therapy
|
US10973834B2
(en)
|
2018-04-16 |
2021-04-13 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
CA3096549A1
(en)
|
2018-04-16 |
2019-10-24 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzymes and uses thereof
|
US10869888B2
(en)
*
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
CN111989342A
(zh)
|
2018-04-18 |
2020-11-24 |
艾克隆株式会社 |
开关分子以及可转换嵌合抗原受体
|
WO2019204496A1
(en)
*
|
2018-04-19 |
2019-10-24 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating melanoma with a chimeric antigen receptor
|
TWI712412B
(zh)
|
2018-04-19 |
2020-12-11 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
CN112218865B
(zh)
|
2018-04-24 |
2024-03-12 |
沃泰克斯药物股份有限公司 |
喋啶酮化合物及其用途
|
CN112236428A
(zh)
|
2018-04-24 |
2021-01-15 |
默克专利股份有限公司 |
抗增殖化合物及其用途
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
JP2021522790A
(ja)
|
2018-05-02 |
2021-09-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
ホスホリパーゼa2受容体キメラ自己受容体t細胞の組成物および方法
|
KR20210044736A
(ko)
|
2018-05-03 |
2021-04-23 |
주노 쎄러퓨티크스 인코퍼레이티드 |
키메라 항원 수용체(car) t세포 요법과 키나제 억제제의 조합요법
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’-環二核苷酸
|
CN108753774B
(zh)
*
|
2018-05-03 |
2021-03-30 |
山东省齐鲁细胞治疗工程技术有限公司 |
干扰il-6表达的cd19-car-t细胞及其应用
|
CN112424342A
(zh)
|
2018-05-08 |
2021-02-26 |
生命科技公司 |
用于培养和扩增细胞的组合物和方法
|
KR20210008502A
(ko)
|
2018-05-11 |
2021-01-22 |
크리스퍼 테라퓨틱스 아게 |
암을 치료하기 위한 방법 및 조성물
|
WO2019222112A1
(en)
|
2018-05-14 |
2019-11-21 |
Gilead Sciences, Inc. |
Mcl-1 inhibitors
|
EP3794348A4
(en)
|
2018-05-18 |
2022-03-09 |
The Johns Hopkins University |
CELL-FREE DNA FOR EVALUATION AND/OR TREATMENT OF CANCER
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CN108715859B
(zh)
*
|
2018-05-31 |
2021-08-03 |
中国医学科学院血液病医院(中国医学科学院血液学研究所) |
靶向cd22的嵌合抗原受体及其应用
|
WO2019232370A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
SG11202011541SA
(en)
|
2018-06-01 |
2020-12-30 |
Kite Pharma Inc |
Chimeric antigen receptor t cell therapy
|
CN112384531A
(zh)
|
2018-06-01 |
2021-02-19 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
TW202016139A
(zh)
|
2018-06-13 |
2020-05-01 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
KR20190141511A
(ko)
*
|
2018-06-14 |
2019-12-24 |
주식회사 녹십자랩셀 |
신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
AU2019288669A1
(en)
|
2018-06-21 |
2021-01-21 |
B-Mogen Biotechnologies, Inc. |
Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
|
EP3810780A1
(en)
|
2018-06-22 |
2021-04-28 |
Kite Pharma Eu B.V. |
Compositions and methods for making engineered t cells
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020014643A1
(en)
|
2018-07-13 |
2020-01-16 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
JPWO2020017479A1
(ja)
|
2018-07-17 |
2021-08-02 |
ノイルイミューン・バイオテック株式会社 |
抗gpc3一本鎖抗体を含むcar
|
EA202190304A1
(ru)
|
2018-07-18 |
2022-01-21 |
Эмджен Инк. |
Химерные рецепторы к steap1 и способы их применения
|
JP7404335B2
(ja)
|
2018-07-19 |
2023-12-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Bcma特異性を有するキメラ抗原受容体およびその使用
|
CN108949759B
(zh)
*
|
2018-07-23 |
2021-06-01 |
合肥一兮生物科技有限公司 |
敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用
|
CN112533953A
(zh)
|
2018-08-02 |
2021-03-19 |
凯德药业股份有限公司 |
嵌合抗原受体疗法t细胞扩增动力学及其用途
|
KR20210059715A
(ko)
|
2018-08-09 |
2021-05-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
통합된 핵산 평가 방법
|
EP3833742A2
(en)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
SG11202101169PA
(en)
*
|
2018-08-10 |
2021-03-30 |
Eutilex Co Ltd |
Chimeric antigen receptor that binds hla-dr and car-t cell
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
CN110856724B
(zh)
*
|
2018-08-24 |
2022-05-27 |
杭州康万达医药科技有限公司 |
包含核酸及car修饰的免疫细胞的治疗剂及其应用
|
EP3844187A1
(en)
|
2018-08-28 |
2021-07-07 |
Vor Biopharma, Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
BR112021003830A2
(pt)
|
2018-08-28 |
2021-07-20 |
Fred Hutchinson Cancer Research Center |
métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
|
US20220348682A1
(en)
|
2018-08-30 |
2022-11-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
AU2019331496A1
(en)
|
2018-08-31 |
2021-03-18 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20220089587A1
(en)
|
2018-09-07 |
2022-03-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
SG11202102108QA
(en)
|
2018-09-11 |
2021-04-29 |
Juno Therapeutics Inc |
Methods for mass spectrometry analysis of engineered cell compositions
|
AU2019345151A1
(en)
|
2018-09-19 |
2021-04-29 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant CD80 fusion proteins and related constructs
|
US11584799B2
(en)
|
2018-09-24 |
2023-02-21 |
Medical College Of Wisconsin, Inc. |
Anti-CD30 antibodies and methods for treating CD30+ cancer
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
US20200102370A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
BR112021006182A2
(pt)
|
2018-10-01 |
2021-06-29 |
Adicet Bio, Inc. |
composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US11179397B2
(en)
|
2018-10-03 |
2021-11-23 |
Gilead Sciences, Inc. |
Imidazopyrimidine derivatives
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
US11851663B2
(en)
|
2018-10-14 |
2023-12-26 |
Snipr Biome Aps |
Single-vector type I vectors
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
EP3872093A4
(en)
|
2018-10-22 |
2022-10-19 |
Shanghai Genbase Biotechnology Co., Ltd. |
ANTI-CLDN18.2 ANTIBODIES AND USES THEREOF
|
CA3117539A1
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1 t cell receptors and methods of use thereof
|
CN112955435A
(zh)
|
2018-10-24 |
2021-06-11 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
US20210379149A1
(en)
*
|
2018-10-25 |
2021-12-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
US20210388389A1
(en)
|
2018-10-30 |
2021-12-16 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
MX2021005047A
(es)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences Inc |
Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
|
JP2022512872A
(ja)
|
2018-10-31 |
2022-02-07 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞の選択および刺激のための方法ならびにそのための装置
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
WO2020092848A2
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
WO2020097132A1
(en)
|
2018-11-06 |
2020-05-14 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
EP3876950A4
(en)
*
|
2018-11-07 |
2022-11-30 |
SOTIO Biotech Inc. |
ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CAR) IN ASSOCIATION WITH TRANS-CO-STIMULATOR MOLECULES AND THEIR THERAPEUTIC USES
|
CN109467604A
(zh)
*
|
2018-11-07 |
2019-03-15 |
南京卡提医学科技有限公司 |
嵌合抗原受体DAP12-T2A-CD8α-CD19scFv-TREM1及其用途
|
CN109503717A
(zh)
*
|
2018-11-07 |
2019-03-22 |
南京卡提医学科技有限公司 |
嵌合抗原受体DAP12-T2A-CD8α-CD19scfv-NKp44及其用途
|
US20220008477A1
(en)
|
2018-11-08 |
2022-01-13 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
AU2019378883A1
(en)
|
2018-11-14 |
2021-06-03 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for T cell delivery
|
KR20210104713A
(ko)
|
2018-11-16 |
2021-08-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 악성 종양 치료를 위한 조작된 t 세포 투약 방법
|
CN113286813A
(zh)
|
2018-11-19 |
2021-08-20 |
得克萨斯大学体系董事会 |
用于car和tcr转导的模块化多顺反子载体
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
CN113272427A
(zh)
|
2018-11-28 |
2021-08-17 |
得克萨斯大学体系董事会 |
免疫细胞的多重基因组编辑以增强功能性和对抑制环境的抵抗力
|
KR20210096648A
(ko)
|
2018-11-29 |
2021-08-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
자연 살해 세포의 생체외 확장을 위한 방법 및 이의 용도
|
JP2022513685A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
CN113692285A
(zh)
|
2018-11-30 |
2021-11-23 |
朱诺治疗学股份有限公司 |
在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
|
WO2020117952A2
(en)
|
2018-12-05 |
2020-06-11 |
Genentech, Inc. |
Diagnostic methods and compositions for cancer immunotherapy
|
TW202100747A
(zh)
*
|
2018-12-07 |
2021-01-01 |
中國大陸商亘喜生物科技(上海)有限公司 |
用於免疫治療之組合物及方法
|
SG11202106049RA
(en)
|
2018-12-10 |
2021-07-29 |
Amgen Inc |
Mutated piggybac transposase
|
EP3894011A1
(en)
|
2018-12-11 |
2021-10-20 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
CA3122762A1
(en)
|
2018-12-12 |
2020-06-18 |
Kite Pharma, Inc. |
Chimeric antigen and t cell receptors and methods of use
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
EP3670530A1
(en)
|
2018-12-18 |
2020-06-24 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2020132586A1
(en)
|
2018-12-21 |
2020-06-25 |
Neon Therapeutics, Inc. |
Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
|
CN113382741A
(zh)
*
|
2019-01-06 |
2021-09-10 |
艾宾妥斯生物公司 |
Car t细胞方法和构建体
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
CN113365660A
(zh)
|
2019-01-29 |
2021-09-07 |
朱诺治疗学股份有限公司 |
对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
|
EP3924387A2
(en)
|
2019-02-15 |
2021-12-22 |
University Of Southern California |
Lym-1 and lym-2 antibody compositions and improved car constructs
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
EP3930763A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Mesoporous silica particles compositions for viral delivery
|
AU2020231308A1
(en)
|
2019-03-01 |
2021-08-19 |
Allogene Therapeutics, Inc. |
DLL3 targeting chimeric antigen receptors and binding agents
|
EP3931310A1
(en)
|
2019-03-01 |
2022-01-05 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
MX2021010670A
(es)
|
2019-03-05 |
2021-11-12 |
Nkarta Inc |
Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
US20220143061A1
(en)
|
2019-03-07 |
2022-05-12 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
DK3934757T3
(da)
|
2019-03-07 |
2023-04-17 |
Inst Of Organic Chemistry And Biochemistry Ascr V V I |
2'3'-cykliske dinukleotider og prodrugs deraf
|
KR20210149251A
(ko)
|
2019-03-08 |
2021-12-08 |
옵시디안 테라퓨틱스, 인크. |
조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
|
CA3128971A1
(en)
|
2019-03-08 |
2020-09-17 |
Klinikum Der Universitat Munchen |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
EA202192555A1
(ru)
|
2019-03-19 |
2021-11-25 |
Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн |
Комбинированная терапия для лечения рака
|
WO2020191316A1
(en)
|
2019-03-21 |
2020-09-24 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
CA3135569A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
CN113939300A
(zh)
|
2019-04-05 |
2022-01-14 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
JP2022529741A
(ja)
|
2019-04-26 |
2022-06-23 |
アロジーン セラピューティクス,インコーポレイテッド |
同種car t細胞を製造する方法
|
CA3134308A1
(en)
|
2019-04-26 |
2020-10-29 |
Thomas Charles PERTEL |
Rituximab-resistant chimeric antigen receptors and uses thereof
|
BR112021021542A2
(pt)
|
2019-04-30 |
2022-04-19 |
Crispr Therapeutics Ag |
Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19
|
AU2020265749A1
(en)
|
2019-05-01 |
2022-01-06 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
|
MX2021013219A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos.
|
JP2022532865A
(ja)
|
2019-05-03 |
2022-07-20 |
カイト ファーマ インコーポレイテッド |
キメラ抗原受容体免疫療法の投与方法
|
JP2022531911A
(ja)
*
|
2019-05-07 |
2022-07-12 |
グレイセル・バイオテクノロジーズ(シャンハイ)カンパニー・リミテッド |
Bcmaを標的とする操作された免疫細胞及びその使用
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
AU2020279371A1
(en)
|
2019-05-22 |
2021-12-23 |
Leidos, Inc. |
LAG 3 binding peptides
|
US20220251538A1
(en)
|
2019-05-23 |
2022-08-11 |
Matjaz Vogelsang |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
KR20220034739A
(ko)
|
2019-05-31 |
2022-03-18 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
KR20220017430A
(ko)
*
|
2019-06-05 |
2022-02-11 |
추가이 세이야쿠 가부시키가이샤 |
항체 절단 부위 결합 분자
|
EP3980530A1
(en)
|
2019-06-07 |
2022-04-13 |
Juno Therapeutics, Inc. |
Automated t cell culture
|
EP3983537A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
MX2021015097A
(es)
|
2019-06-12 |
2022-04-01 |
Obsidian Therapeutics Inc |
Composiciones de ca2 y metodos para regulación ajustable.
|
CA3142361A1
(en)
|
2019-06-12 |
2020-12-17 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
CN114391021A
(zh)
|
2019-06-21 |
2022-04-22 |
凯德药业股份有限公司 |
TGF-β受体和使用方法
|
JP2022539032A
(ja)
|
2019-06-24 |
2022-09-07 |
チルドレンズ ホスピタル ロサンゼルス |
ヒト胸腺細胞形成およびt細胞機能を強化するためのbcl11b過剰発現
|
BR112021026376A2
(pt)
|
2019-06-25 |
2022-05-10 |
Gilead Sciences Inc |
Proteínas de fusão flt3l-fc e métodos de uso
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質-金属水酸化物錯体およびその方法
|
CN114729383A
(zh)
|
2019-07-02 |
2022-07-08 |
弗莱德哈钦森癌症研究中心 |
重组ad35载体及相关基因疗法改进
|
CN114269783B
(zh)
|
2019-07-02 |
2024-03-26 |
美国政府(由卫生和人类服务部的部长所代表) |
结合egfrviii的单克隆抗体及其应用
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
US20220267726A1
(en)
|
2019-07-18 |
2022-08-25 |
Gpb Scientific, Inc. |
Ordered processing of blood products to produce therapeutically active cells
|
KR20220042161A
(ko)
|
2019-07-23 |
2022-04-04 |
엥스띠뛰 퀴리 |
Suv39h1에 결함이 있는 면역 세포
|
CN114174345A
(zh)
|
2019-07-24 |
2022-03-11 |
瑞泽恩制药公司 |
具有mage-a4特异性的嵌合抗原受体和其用途
|
CN110305849B
(zh)
*
|
2019-08-01 |
2021-03-30 |
广东万海细胞生物科技有限公司 |
稳定表达car的t细胞及其制备方法与应用
|
GB201911066D0
(en)
|
2019-08-02 |
2019-09-18 |
Achilles Therapeutics Ltd |
T cell therapy
|
JP2022543702A
(ja)
*
|
2019-08-09 |
2022-10-13 |
エイ2・バイオセラピューティクス・インコーポレイテッド |
ヘテロ接合性の喪失に応答する細胞表面受容体
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법
|
CN114600172A
(zh)
|
2019-08-30 |
2022-06-07 |
朱诺治疗学股份有限公司 |
用于将细胞分类的机器学习方法
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
AU2020343407A1
(en)
|
2019-09-02 |
2022-03-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immunotherapy targeting tumor neoantigenic peptides
|
EP4025688A1
(en)
|
2019-09-03 |
2022-07-13 |
Allogene Therapeutics, Inc. |
Methods of preparing t cells for t cell therapy
|
CA3152525A1
(en)
|
2019-09-03 |
2021-03-11 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
CA3153700A1
(en)
|
2019-09-09 |
2021-03-18 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
CA3150224A1
(en)
|
2019-09-10 |
2021-03-18 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
US20220347216A1
(en)
*
|
2019-09-13 |
2022-11-03 |
Ohio State Innovation Foundation |
Nk cell immunotherapy compositions, methods of making and methods of using same
|
BR112022004451A2
(pt)
|
2019-09-13 |
2022-06-21 |
Nimbus Saturn Inc |
Antagonistas de hpk1 e usos dos mesmos
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
EP4032907A4
(en)
|
2019-09-20 |
2023-07-05 |
Shanghai Genbase Biotechnology Co., Ltd. |
BCMA-TARGETING CHEMERA ANTIGENIC ANTIBODIES AND RECEPTOR
|
WO2021055915A1
(en)
*
|
2019-09-20 |
2021-03-25 |
The University Of North Carolina At Chapel Hill |
Modified t cells and methods of preparing the same
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
KR102287180B1
(ko)
*
|
2019-10-01 |
2021-08-09 |
충북대학교 산학협력단 |
Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
WO2021067788A1
(en)
|
2019-10-03 |
2021-04-08 |
Artisan Development Labs, Inc. |
Crispr systems with engineered dual guide nucleic acids
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
KR20220085796A
(ko)
|
2019-10-18 |
2022-06-22 |
포티 세븐, 인코포레이티드 |
골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
|
EP4048304A1
(en)
|
2019-10-22 |
2022-08-31 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
CN110679588A
(zh)
*
|
2019-10-23 |
2020-01-14 |
厦门生命互联科技有限公司 |
一种嵌合抗原受体t细胞冻存介质及用途
|
EP4048696A1
(en)
|
2019-10-23 |
2022-08-31 |
Kite Pharma, Inc. |
Anti-idiotypic antigen binding molecules and methods of use thereof
|
TWI717880B
(zh)
*
|
2019-10-24 |
2021-02-01 |
中國醫藥大學附設醫院 |
Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
|
BR112022008023A2
(pt)
|
2019-10-30 |
2022-07-12 |
Juno Therapeutics Gmbh |
Dispositivos de seleção e/ou estimulação de células e métodos de uso
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
KR20220091576A
(ko)
|
2019-10-31 |
2022-06-30 |
포티 세븐, 인코포레이티드 |
혈액암의 항-cd47 및 항-cd20 기반 치료
|
WO2021085504A1
(ja)
|
2019-11-01 |
2021-05-06 |
京都府公立大学法人 |
B細胞抗体受容体、及びその利用
|
CN114980918A
(zh)
|
2019-11-07 |
2022-08-30 |
朱诺治疗学股份有限公司 |
T细胞疗法与(s)-3-[4-(4-吗啉-4-基甲基-苄氧基)-1-氧代-1,3-二氢-异吲哚-2-基]-哌啶-2,6-二酮的组合
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
KR20210061956A
(ko)
|
2019-11-20 |
2021-05-28 |
주식회사 지아이셀 |
T 세포 배양용 배지 조성물 및 이를 이용한 t 세포의 배양 방법
|
US11591339B2
(en)
|
2019-11-26 |
2023-02-28 |
Ikena Oncology, Inc. |
Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
EP4070097A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
|
KR20220122656A
(ko)
|
2019-12-06 |
2022-09-02 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Gprc5d-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
|
IL293430A
(en)
|
2019-12-06 |
2022-07-01 |
Juno Therapeutics Inc |
Anti-idiotic antibodies to bcma-targeted binding domains and related compositions and methods
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
IL293917A
(en)
|
2019-12-17 |
2022-08-01 |
Kymera Therapeutics Inc |
Iraq joints and their uses
|
CN115052662A
(zh)
|
2019-12-20 |
2022-09-13 |
诺华股份有限公司 |
抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
|
KR20220151160A
(ko)
|
2019-12-23 |
2022-11-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Smarca 분해제 및 이의 용도
|
KR20220131918A
(ko)
|
2019-12-24 |
2022-09-29 |
카나 바이오사이언스, 인코포레이션 |
다이아실글리세롤 키나제 조절 화합물
|
JP7088902B2
(ja)
*
|
2019-12-27 |
2022-06-21 |
クレージュ メディカル カンパニー,リミテッド |
キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するtリンパ球
|
CN115209996A
(zh)
|
2019-12-28 |
2022-10-18 |
Gpb科学有限公司 |
用于处理颗粒和细胞的微流体盒
|
CN113150167A
(zh)
*
|
2020-01-22 |
2021-07-23 |
中国人民解放军总医院第五医学中心 |
一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计
|
WO2021150919A1
(en)
|
2020-01-23 |
2021-07-29 |
The Children's Medical Center Corporation |
Stroma-free t cell differentiation from human pluripotent stem cells
|
WO2021150804A1
(en)
|
2020-01-24 |
2021-07-29 |
Regeneron Pharmaceuticals, Inc. |
Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
|
IL294724A
(en)
|
2020-01-24 |
2022-09-01 |
Juno Therapeutics Inc |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in stress cell therapy
|
CN115427550A
(zh)
|
2020-01-28 |
2022-12-02 |
朱诺治疗学股份有限公司 |
T细胞转导方法
|
WO2021155897A1
(en)
|
2020-02-03 |
2021-08-12 |
MVZ Prof. Niendorf Pathologie Hamburg-West GmbH |
Marker set for the diagnosis and treatment of cancer
|
AU2021219764A1
(en)
|
2020-02-12 |
2022-09-01 |
Juno Therapeutics, Inc. |
BCMA-directed chimeric antigen receptor T cell compositions and methods and uses thereof
|
IL295384A
(en)
|
2020-02-12 |
2022-10-01 |
Juno Therapeutics Inc |
Preparations of t cells with a chimeric antigen receptor directed against cd19 and methods and uses thereof
|
BR112022014623A2
(pt)
|
2020-02-14 |
2022-09-13 |
Jounce Therapeutics Inc |
Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
KR20220146530A
(ko)
|
2020-02-27 |
2022-11-01 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포의 제조 방법
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
CN111269326A
(zh)
*
|
2020-02-28 |
2020-06-12 |
南京北恒生物科技有限公司 |
新型嵌合抗原受体及其用途
|
US11753403B2
(en)
|
2020-03-03 |
2023-09-12 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
WO2022074464A2
(en)
|
2020-03-05 |
2022-04-14 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
EP4117716A2
(en)
|
2020-03-10 |
2023-01-18 |
Massachusetts Institute of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
AU2021232853A1
(en)
|
2020-03-10 |
2022-09-22 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技(香港)有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
BR112022018678A2
(pt)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
Degradadores de mdm2 e usos dos mesmos
|
KR20230006819A
(ko)
|
2020-03-31 |
2023-01-11 |
사나 바이오테크놀로지, 인크. |
표적화된 지질 입자 및 이의 조성물 및 용도
|
EP3892720A1
(en)
|
2020-04-06 |
2021-10-13 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Presenting cell and use thereof in cell therapy
|
BR112022020333A2
(pt)
|
2020-04-10 |
2022-11-22 |
Juno Therapeutics Inc |
Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b
|
US20230340040A1
(en)
*
|
2020-04-14 |
2023-10-26 |
St. Jude Children's Research Hospital, Inc. |
Chimeric myd88 receptors
|
US20210324331A1
(en)
*
|
2020-04-15 |
2021-10-21 |
Amgen Inc. |
Process for generating genetically engineered autologous t cells
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
KR20230002554A
(ko)
|
2020-04-28 |
2023-01-05 |
아킬레스 테라퓨틱스 유케이 리미티드 |
T 세포 요법
|
MX2022013530A
(es)
|
2020-04-28 |
2023-02-01 |
Juno Therapeutics Inc |
Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador.
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
US20230039553A1
(en)
|
2020-05-01 |
2023-02-09 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021226063A1
(en)
|
2020-05-05 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Car comprising cd28 zeta and cd3 zeta
|
US20230212243A1
(en)
|
2020-05-12 |
2023-07-06 |
Institut Curie |
Neoantigenic Epitopes Associated with SF3B1 Mutations
|
WO2021231657A1
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
US20230190780A1
(en)
*
|
2020-05-15 |
2023-06-22 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
JP2023526416A
(ja)
|
2020-05-21 |
2023-06-21 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Vgll1特異性を有するt細胞受容体およびその使用法
|
BR112022024027A2
(pt)
|
2020-05-27 |
2023-02-07 |
Antion Biosciences Sa |
Moléculas adaptadoras para redirecionar células t car para um antígeno de interesse
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
CN115867294A
(zh)
|
2020-06-04 |
2023-03-28 |
凯瑞斯马治疗公司 |
嵌合抗原受体的新型构建体
|
WO2021244654A1
(en)
*
|
2020-06-05 |
2021-12-09 |
Nanjing Legend Biotech Co., Ltd. |
Activation induced cytokine production in immune cells
|
JP2023530238A
(ja)
|
2020-06-08 |
2023-07-14 |
ヤンセン バイオテツク,インコーポレーテツド |
キメラ抗原発現免疫細胞のインビトロ腫瘍殺傷活性を決定するための細胞ベースのアッセイ
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
CN116234558A
(zh)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
|
CA3188656A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
KR102297396B1
(ko)
|
2020-07-29 |
2021-09-06 |
(주)티카로스 |
면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
|
US20230303974A1
(en)
|
2020-07-30 |
2023-09-28 |
Institut Curie |
Immune Cells Defective for SOCS1
|
US11578102B2
(en)
|
2020-07-31 |
2023-02-14 |
Leidos, Inc. |
LAG3 binding peptides
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20230324408A1
(en)
|
2020-08-05 |
2023-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
MX2023001831A
(es)
|
2020-08-13 |
2023-06-29 |
Sana Biotechnology Inc |
Métodos de tratamiento de pacientes sensibilizados con células hipoinmunogénicas y métodos y composiciones asociados.
|
AU2021325947A1
(en)
|
2020-08-13 |
2023-03-02 |
Yale University |
Compositions and methods for engineering and selection of CAR T cells with desired phenotypes
|
WO2022036041A1
(en)
|
2020-08-14 |
2022-02-17 |
Kite Pharma, Inc |
Improving immune cell function
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
CA3188862A1
(en)
|
2020-08-20 |
2022-02-24 |
Carl Alexander Kamb |
Compositions and methods for treating mesothelin positive cancers
|
MX2023002017A
(es)
|
2020-08-20 |
2023-04-28 |
A2 Biotherapeutics Inc |
Composiciones y métodos para tratar cánceres positivos para ceacam.
|
IL300489A
(en)
|
2020-08-21 |
2023-04-01 |
Novartis Ag |
Compositions and methods for in vivo production of CAR expressing cells
|
US20220064596A1
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
US20230302135A1
(en)
*
|
2020-08-26 |
2023-09-28 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Hybrid allosteric receptor-engineered stem cells
|
EP4225444A1
(en)
|
2020-10-12 |
2023-08-16 |
Leidos, Inc. |
Immunomodulatory peptides
|
JP2023545472A
(ja)
*
|
2020-10-16 |
2023-10-30 |
ネオンク テクノロジーズ インク. |
Cns感染症の治療のためのpohとレムデシビルとの組み合わせ
|
CN116528879A
(zh)
|
2020-10-28 |
2023-08-01 |
凯德药业股份有限公司 |
用于表征t细胞杂质的流式细胞术方法
|
CN116390933A
(zh)
|
2020-11-06 |
2023-07-04 |
诺华股份有限公司 |
治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
|
CA3201499A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
AU2021378316A1
(en)
|
2020-11-13 |
2023-06-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
CN112195250A
(zh)
*
|
2020-11-20 |
2021-01-08 |
山东省医学科学院附属医院 |
一种qPCR试剂盒及应用
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
CA3202218A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
WO2022140159A1
(en)
|
2020-12-24 |
2022-06-30 |
Kite Pharma, Inc. |
Prostate cancer chimeric antigen receptors
|
WO2022147444A2
(en)
|
2020-12-30 |
2022-07-07 |
Alaunos Therapeutics, Inc. |
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
|
AU2021412988A1
(en)
|
2020-12-31 |
2023-06-15 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating car-t activity
|
CN116917737A
(zh)
|
2021-01-10 |
2023-10-20 |
凯德药业股份有限公司 |
T细胞疗法
|
KR20230151513A
(ko)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Cd8 표적 바이러스 벡터의 용도
|
WO2022148979A1
(en)
|
2021-01-11 |
2022-07-14 |
Bicycletx Limited |
Methods for treating cancer
|
JP2024505428A
(ja)
|
2021-01-14 |
2024-02-06 |
アンスティテュ キュリー |
Her2単一ドメイン抗体バリアントおよびそのcar
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
JP2024504728A
(ja)
|
2021-01-26 |
2024-02-01 |
サイトケアズ (シャンハイ) インコーポレイテッド |
キメラ抗原受容体(car)構築物およびcar構築物を発現するnk細胞
|
JP2024505184A
(ja)
*
|
2021-01-27 |
2024-02-05 |
エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド |
B細胞悪性腫瘍に対する二重特異性car t細胞
|
TW202246517A
(zh)
|
2021-01-28 |
2022-12-01 |
美商異基因治療有限公司 |
用於轉導免疫細胞之方法
|
KR20230157315A
(ko)
|
2021-01-28 |
2023-11-16 |
리제너론 파마슈티칼스 인코포레이티드 |
사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
|
KR20230152692A
(ko)
|
2021-02-02 |
2023-11-03 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
CA3207380A1
(en)
|
2021-02-15 |
2022-08-18 |
Haojing RONG |
Irak4 degraders and uses thereof
|
EP4294950A1
(en)
|
2021-02-20 |
2023-12-27 |
Kite Pharma, Inc. |
Gene markers for selecting immunotherapies
|
JP2024509853A
(ja)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法およびdgk阻害剤の組合せ
|
JP2024509192A
(ja)
|
2021-03-05 |
2024-02-29 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニスト及びその使用
|
WO2022183502A1
(zh)
|
2021-03-05 |
2022-09-09 |
上海吉倍生物技术有限公司 |
抗cldn6抗体及其用途
|
EP4304634A1
(en)
|
2021-03-11 |
2024-01-17 |
Institut Curie |
Transmembrane neoantigenic peptides
|
KR20230155521A
(ko)
|
2021-03-11 |
2023-11-10 |
카이트 파마 인코포레이티드 |
면역 세포 기능의 향상
|
EP4304632A2
(en)
|
2021-03-11 |
2024-01-17 |
Mnemo Therapeutics |
Tumor neoantigenic peptides
|
AU2022235060A1
(en)
|
2021-03-11 |
2023-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tumor neoantigenic peptides and uses thereof
|
KR20230157371A
(ko)
|
2021-03-17 |
2023-11-16 |
다이이찌 산쿄 가부시키가이샤 |
항아세틸콜린 수용체 자기 항체에 대한 키메라 수용체를 코드하는 유전자
|
EP4314814A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
EP4314280A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
JP2024513054A
(ja)
|
2021-03-29 |
2024-03-21 |
ジュノー セラピューティクス インコーポレイテッド |
リンパ腫の治療のためのcar t細胞療法および免疫調節化合物の組合せ
|
IL307262A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
GB202109886D0
(en)
|
2021-07-08 |
2021-08-25 |
Achilles Therapeutics Uk Ltd |
Assay
|
WO2022214835A1
(en)
|
2021-04-09 |
2022-10-13 |
Achilles Therapeutics Uk Limited |
Batch release assay for pharmaceutical products relating to t cell therapies
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
JP2024514879A
(ja)
|
2021-04-16 |
2024-04-03 |
イケナ オンコロジー, インコーポレイテッド |
Mek阻害剤及びその使用
|
WO2022221737A1
(en)
|
2021-04-16 |
2022-10-20 |
Juno Therapeutics, Inc. |
T cell therapy in patients who have had prior stem cell transplant
|
CA3216056A1
(en)
|
2021-04-16 |
2022-10-20 |
Kite Pharma, Inc. |
Taci/bcma dual binding molecules
|
IL307612A
(en)
|
2021-04-16 |
2023-12-01 |
Celgene Corp |
Combined therapies with BCMA-directed T-cell therapy
|
EP4323943A1
(en)
|
2021-04-16 |
2024-02-21 |
Kite Pharma, Inc. |
Methods and systems for scheduling a patient-specific immunotherapy procedure
|
EP4326286A2
(en)
*
|
2021-04-23 |
2024-02-28 |
Myeloid Therapeutics, Inc. |
Compositions and methods for conditioning patients for cell therapy
|
JP2024515793A
(ja)
|
2021-04-27 |
2024-04-10 |
ノバルティス アーゲー |
ウイルスベクター生産システム
|
TW202309269A
(zh)
|
2021-04-27 |
2023-03-01 |
日商武田藥品工業股份有限公司 |
重組抗原呈現細胞
|
WO2022235662A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
WO2022234009A2
(en)
|
2021-05-06 |
2022-11-10 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
WO2022241151A2
(en)
|
2021-05-14 |
2022-11-17 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
BR112023024231A2
(pt)
|
2021-05-19 |
2024-01-30 |
Sana Biotechnology Inc |
Células t primárias rhd negativas hipoimunogênicas
|
CN117677633A
(zh)
|
2021-05-24 |
2024-03-08 |
凯德药业股份有限公司 |
基于nkg2d的嵌合抗原受体
|
BR112023024501A2
(pt)
*
|
2021-05-26 |
2024-02-15 |
Univ Emory |
Método de tratamento da síndrome de down, método de melhora de eficácia de uma vacina e método de tratamento de câncer
|
IL308097A
(en)
|
2021-05-27 |
2023-12-01 |
Sana Biotechnology Inc |
Hypoimmunogenic cells that include transgenic HLA-E or HLA-G
|
EP4347620A1
(en)
|
2021-05-28 |
2024-04-10 |
Sana Biotechnology, Inc. |
Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
WO2022261061A1
(en)
|
2021-06-08 |
2022-12-15 |
Kite Pharma, Inc. |
Gpc3 binding molecules
|
CA3223311A1
(en)
|
2021-06-18 |
2022-12-22 |
Andrea BARGHETTI |
Compositions and methods for targeting, editing or modifying human genes
|
CA3223074A1
(en)
|
2021-06-22 |
2022-12-29 |
Achilles Therapeutics Uk Limited |
A method for producing antigen specific t cells
|
CA3220923A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
US20230046340A1
(en)
|
2021-06-23 |
2023-02-16 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CA3222595A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CA3224374A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
US20230027004A1
(en)
|
2021-07-01 |
2023-01-26 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
WO2023278811A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
IL309431A
(en)
|
2021-07-02 |
2024-02-01 |
Kite Pharma Inc |
A method for identifying variants in gene products from gene constructs used in cell therapy applications
|
WO2023281097A1
(en)
|
2021-07-09 |
2023-01-12 |
Immunic Ag |
Methods for treating cancer
|
CA3225283A1
(en)
|
2021-07-14 |
2023-01-19 |
Sonja SCHREPFER |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
CA3224974A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Albert Ruzo Matias |
Polycistronic vectors for cell-based therapies
|
WO2023004300A2
(en)
*
|
2021-07-19 |
2023-01-26 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor (car)-t signaling optimization for tuning antigen activation threshold
|
US20230190799A1
(en)
*
|
2021-07-21 |
2023-06-22 |
City Of Hope |
Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
|
WO2023010114A1
(en)
|
2021-07-30 |
2023-02-02 |
Kite Pharma, Inc. |
Monitoring and management of cell therapy-induced toxicities
|
AU2022324040A1
(en)
|
2021-08-04 |
2024-02-22 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
TW202321457A
(zh)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
靶向cd4之病毒載體之用途
|
WO2023019128A1
(en)
*
|
2021-08-09 |
2023-02-16 |
The Trustees Of The University Of Pennyslvania |
Optimizing t cell differentiation state with micrornas
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
IL310702A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
IL310691A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
AR126838A1
(es)
|
2021-08-20 |
2023-11-22 |
Novartis Ag |
Métodos para preparar células que expresan receptores de antígeno quiméricos
|
WO2023025788A1
(en)
|
2021-08-24 |
2023-03-02 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Il-10 expressing cells for enhanced cancer immunotherapies
|
US20230150997A1
(en)
|
2021-08-25 |
2023-05-18 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
AU2022349103A1
(en)
|
2021-09-27 |
2024-03-28 |
Sotio Biotech Inc. |
Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
|
US20230303655A1
(en)
|
2021-10-18 |
2023-09-28 |
Kite Pharma, Inc. |
Signaling domains for chimeric antigen receptors
|
TW202330504A
(zh)
|
2021-10-28 |
2023-08-01 |
美商基利科學股份有限公司 |
嗒𠯤—3(2h)—酮衍生物
|
US11919869B2
(en)
|
2021-10-29 |
2024-03-05 |
Gilead Sciences, Inc. |
CD73 compounds
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023091909A1
(en)
|
2021-11-16 |
2023-05-25 |
Sotio Biotech Inc. |
Treatment of myxoid/round cell liposarcoma patients
|
WO2023092119A2
(en)
|
2021-11-22 |
2023-05-25 |
Ludwig Institute For Cancer Research Ltd |
Methods for predicting responsiveness to a cancer therapy
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
TW202342757A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科附著醣蛋白
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
TW202342498A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科融合醣蛋白
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20230242508A1
(en)
|
2021-12-22 |
2023-08-03 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023129929A1
(en)
|
2021-12-30 |
2023-07-06 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
US20230227779A1
(en)
|
2022-01-19 |
2023-07-20 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment
|
WO2023139269A1
(en)
|
2022-01-21 |
2023-07-27 |
Mnemo Therapeutics |
Modulation of suv39h1 expression by rnas
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023154890A2
(en)
*
|
2022-02-11 |
2023-08-17 |
Fred Hutchinson Cancer Center |
Chimeric antigen receptors binding steap1
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023159001A1
(en)
|
2022-02-15 |
2023-08-24 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
TW202340457A
(zh)
|
2022-02-28 |
2023-10-16 |
美商凱特製藥公司 |
同種異體治療細胞
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
US20230373950A1
(en)
|
2022-03-17 |
2023-11-23 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023178348A1
(en)
|
2022-03-18 |
2023-09-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically engineered t-cell co-receptors and methods of use thereof
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
WO2023180552A1
(en)
|
2022-03-24 |
2023-09-28 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
GB202204386D0
(en)
|
2022-03-28 |
2022-05-11 |
Cambridge Entpr Ltd |
Engineered immune cell platform
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
WO2023196933A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
TW202400138A
(zh)
|
2022-04-21 |
2024-01-01 |
美商基利科學股份有限公司 |
Kras g12d調節化合物
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
WO2023230272A1
(en)
|
2022-05-27 |
2023-11-30 |
Kite Pharma, Inc. |
Non-viral delivery of cell therapy constructs
|
US20230392119A1
(en)
|
2022-05-27 |
2023-12-07 |
Kite Pharma, Inc. |
Compositions and methods for preparing engineered lymphocytes for cell therapy
|
US20230399614A1
(en)
|
2022-06-09 |
2023-12-14 |
Kite Pharma, Inc. |
Methods of preparing lymphocytes for cell therapy
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2023242343A1
(en)
|
2022-06-15 |
2023-12-21 |
Immunoscape Pte. Ltd. |
Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024033879A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Hypoimmunogenic modified cells
|
WO2024040208A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|
WO2024044670A1
(en)
|
2022-08-26 |
2024-02-29 |
Kite Pharma, Inc. |
Improving immune cell function
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
WO2024073583A1
(en)
|
2022-09-30 |
2024-04-04 |
Caribou Biosciences, Inc. |
Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|